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1. Introduction 
 
Robert Koch (1843-1910) first confirmed the role of bacteria as causative organisms of 
infectious diseases by his studies on Bacillus anthracis, the causative organism of anthrax.1 
The targeted treatment of a bacterial infection using an antimicrobial agent was initially 
performed in 1910 by Paul Ehrlich (1845-1915) and Sahachiro Hata (1873-1938) by the 
successful treatment of syphilis by the use of the chemically synthesized arsenic compound 
arsphenamine (Salvarsan®) (Figure 1).2 This was the foundation of modern antimicrobial 
chemotherapy, the medical treatment of infectious microbial diseases. Since then, multiple 
antimicrobial compounds were developed, illustrated by the timeline in Figure 1. The 
development of novel antimicrobial agents was driven forward by the identification of 
naturally occurring antibiotics. The first antibiotic identified was the β-lactam penicillin, 
which was discovered by Alexander Fleming (1881-1955) in 1928 by the observation that 
growth of a Staphylococcus aureus culture on a solid medium was inhibited in the presence of 
Penicillium notatum.3 Penicillin was introduced into clinical therapy in 1941. 
 
In parallel to the introduction of novel antimicrobial agents, resistant bacteria, which were 
able to overcome the antimicrobial effect of certain drugs, emerged. β-lactam resistance was 
initially discovered in 1940 with the observation of a penicillin-resistant S. aureus.4 An 
emerging threat in health-care facilities nowadays is the spread of multi-drug resistant (MDR) 
and pan-drug resistant (PDR) pathogens. Multi-drug resistance implies non-susceptibility to 
one or more agents of at least three antimicrobial classes, whereby available treatment options 
can be dramatically reduced. Pan-drug resistance implies resistance to all currently available 
antimicrobials which are usually active against the respective organism, which leads to 
untreatable infections. A global challenge in health-care facilities is Acinetobacter baumannii, 
which possesses a high propensity to multi-drug resistance and epidemic spread.5, 6 Until 1970 
Acinetobacter spp. isolates retained susceptibility to almost all available antimicrobials, but 
since the early 1980s the rate of antimicrobial resistance in Acinetobacter spp. isolates is 
raising.7
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Figure 1: Introduction of antimicrobial agents and classes from 1911 to 2011. Green arrows highlight 
the date of introduction of antimicrobial agents and classes. Red arrows highlight the primarily 
detection of β-lactam resistance in 1940, the first detection of a carbapenem-resistant Acinetobacter 
isolate in 1985 and the first report of an outbreak of MDR A. baumannii in a hospital in New York 
City, USA, in 1991.4, 8, 9 
 
Since the early 1990s, the majority of A. baumannii isolates retained susceptibility to the       
β-lactam class of carbapenems. Interestingly, the first carbapenem-resistant A. baumannii 
isolate was reported in 1993, but was isolated in 1985 in parallel to the introduction of 
carbapenems in the clinical treatment of infections.10 Interestingly, at the time of isolation, 
carbapenems have not been in use in the respective hospital.10 To date carbapenems are the 
drugs of choice to treat infections with MDR A. baumannii. However, carbapenem resistance 
in A. baumannii has increased over the years and emerged as a global threat in health-care 
facilities. To illustrate the consequence of Acinetobacter spp. in the clinical setting the 
Acinetobacter genus will be discussed below with a special focus on A. baumannii and 
antimicrobial resistance. 
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1.1 The genus Acinetobacter 
 
The genus Acinetobacter belongs to the family of Moraxellaceae in the class of                       
γ-proteobacteria. Acinetobacter spp. are Gram-negative, strictly aerobic, non-fermentative 
bacteria. Untypical for Moraxellaceae, the cytochrome c oxidase test of Acinetobacter spp. is 
usually negative, indicating the presence of an alternative cytochrome in the respiratory chain. 
The genus Acinetobacter was first proposed in 1954 by Brisou and Prévot, while initial 
detection of an Acinetobacter strain goes back to 1911 when the Dutch microbiologist 
Beijerinck isolated `Micrococcus calcoaceticus´ which was finally re-named as Acinetobacter 
calcoaceticus.11, 12 The term Acinetobacter has originated from the greek term `akinetos´ 
which means “non-motile”. However, the dogma of Acinetobacter being non-motile has been 
disproved. Recent studies have shown that some Acinetobacter species, in particular             
A. baumannii, encode several genes necessary for motility and in fact can be motile when 
growing on semi-solid media in the absence of light.13, 14 
 
1.1.1 Taxonomy of the genus Acinetobacter 
 
The genus Acinetobacter currently comprises 33 distinct species with valid names 
(http://www.bacterio.cict.fr/a/Acinetobacter.html) and 15 provisional taxa which include 
either genomic species (Acinetobacter genomic species) delineated by DNA-DNA 
hybridization6 or species with effectively (but not validated) published names (Table 1). Once 
a proposed novel species name is published on the validation list of the International Journal 
of Systematic and Evolutionary Microbiology (IJSEM), it is accepted as a valid species name 
(http://ijs.sgmjournals.org/site/misc/about.xhtml#VL). Effectively published species names 
are not yet validated by the IJSEM. 
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Table 1: The species composition of the genus Acinetobacter (adapted from 
http://apps.szu.cz/anemec/Classification.pdf). Species names in parentheses are effectively published, 
but have not been validated yet. 
Valid species names Main sources of isolation Reference 
A. baumannii Human, animals Bouvet & Grimont15 
A. baylyi Soil Carr et al.16,  
Vaneechoutte et al.17 
A. beijerinkii  Human, animals, soil, water Nemec et al.18 
A. bereziniae (formerly AGS 10) Human Nemec et al.19,  
Bouvet & Grimont15 
A. boissieri Floral nectar Álvarez-Pérez et al.20 
A. bouvetii Activated sludge Carr et al.16 
A. brisouii Peat Anandham et al.21  
A. calcoaceticus Soil Bouvet & Grimont15 
A. gerneri Activated sludge Carr et al.16 
A. grimontii (= A. junii) Activated sludge Carr et al.16, 
Vaneechoutte et al.22 
A. guillouiae (formerly AGS 11) Human, soil Nemec et al.19, 
Bouvet & Grimont15 
A. gyllenbergii Human Nemec et al.18 
A. haemolyticus Human Bouvet & Grimont15 
A. harbinensis River water Li et al.23 
A. indicus Dumpsite Malhotra et al.24 
A. johnsonii Human, animals Bouvet & Grimont15 
A. junii Human Bouvet & Grimont15 
A. kookii Soil Choi. et al.25 
AGS, Acinetobacter genomic species 
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Table 1 continued: The species composition of the genus Acinetobacter (adapted from 
http://apps.szu.cz/anemec/Classification.pdf). Species names in parentheses are effectively published, 
but have not been validated yet. 
Valid species names Main sources of isolation Reference 
A. lwoffii (formerly AGS 8 and 9) Human, animals Bouvet & Grimont15, 
Tjernberg & Ursing26 
A. nectaris Floral nectar Álvarez-Pérez et al.20 
A. nosocomialis (formerly AGS 13TU) Human Nemec et al.27,  
Tjernberg & Ursing26 
A. parvus Human, animals Nemec et al.28 
A. pittii (formerly AGS 3) Human, soil Nemec et al.27,  
Bouvet & Grimont15 
A. puyangensis Canker bark Li et al.29 
A. qingfengensis Canker bark Li et al.30 
A. radioresistens (formerly AGS 12) Human, soil, cotton Nishimura et al.31,  
Bouvet & Grimont15 
A. rudis Raw  milk, wastewater Vaz-Moreira et al.32 
A. schindleri Human Nemec et al.33 
A. soli Human, soil Kim et al.34 
A. tandoii Activated sludge Carr et al.16 
A. tjernbergiae Activated sludge Carr et al.16 
A. towneri Activated sludge Carr et al.16 
A. ursingii  Human Nemec et al.33 
A. venetianus Sea water Vaneechoutte et al.35,  
Di Cello et al.36 
AGS, Acinetobacter genomic species 
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Table 1 continued: The species composition of the genus Acinetobacter (adapted from 
http://apps.szu.cz/anemec/Classification.pdf). Species names in parentheses are effectively published, 
but have not been validated yet. 
Provisional designations and  published 
species names  
Main sources of isolation Reference 
AGS 6 Human Bouvet & Grimont15 
AGS 13BJ/14TU Human Bouvet & Jeanjean37,  
Tjernberg & Ursing26 
AGS 14BJ Human Bouvet & Jeanjean37 
AGS 15BJ Human Bouvet & Jeanjean37 
AGS 15TU Human Tjernberg & Ursing26 
AGS 16 Human, vegetables Bouvet & Jeanjean37 
AGS 17 Human, soil Bouvet & Jeanjean37 
AGS `between 1 and 3´ Human Gerner-Smidt & Tjernberg38 
AGS `close to 13TU´ Human Gerner-Smidt & Tjernberg38 
`A. antiviralis´ Tobacco plant roots  Lee et al.39 
`A. kyonggiensis´ Sewage Lee & Lee40 
`A. marinus´ Sea water Yoon et al.41 
`A. oleivorans´ Rice paddy Kang et al.42 
`A. oryzae´ Rice Chaudhary et al.43 
`A. seohaensis´ Sea water Yoon et al.41 
`A. septicus´ (= A. ursingii) Human Kilic et al.44,  
Nemec et al.45 
AGS, Acinetobacter genomic species 
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As shown by Vaneechoutte et al. A. grimontii is identical to A. junii, which means that both 
species names belong to the same taxon.22 In addition, Nemec et al. have shown that            
`A. septicus´ is A. ursingii.45 Several Acinetobacter genomic species harbor specific 
abbreviations which correspond to the initials of the authors who first described them, with BJ 
referring to Bouvet and Jeanjean and TU referring to Tjernberg and Ursing. During the last 
years, several provisional designations received valid species names. For example, Bouvet & 
Grimont proposed the species name A. lwoffii for Acinetobacter genomic species 8.15 The 
taxon includes Acinetobacter genomic species 9, as suggested by Tjernberg & Ursing, which 
also showed that Acinetobacter genomic species 12 corresponds to A. radioresistens.26 
Furthermore, Nemec et al. recently proposed species names for Acinetobacter genomic 
species 3, 10, 11 and 13TU, which are now validated as A. pittii, A. bereziniae, A. guillouiae 
and A. nosocomialis, respectively.19, 27 
 
1.1.2 Natural habitats and clinical relevance of Acinetobacter spp. 
 
Species of the genus Acinetobacter can be recovered from environmental samples, like soil, 
vegetables and surface water. For example, A. calcoaceticus, A. pittii, A. johnsonii and            
A. guillouiae have been isolated from soil and water.5 Furthermore, Acinetobacter spp. can 
also be commensals of the human skin, mucous membranes and intestinal tract and are mainly 
isolated as colonizing organisms. Previous studies have reported Acinetobacter carriage rates 
in healthy humans between 25% (fecal colonization) and 44% (skin colonization).46-48 The 
predominant Acinetobacter spp. detected in fecal samples were A. johnsonii and A. guillouiae. 
Frequently skin colonizing Acinetobacter spp. include A. lwoffii, A. johnsonii, A. junii,            
A. pittii, A. radioresistens and Acinetobacter genomic species 15BJ. Although A. baumannii 
and A. nosocomialis have been recovered from vegetables, human skin, body lice or animals, 
both species are mainly recovered from clinical specimens and infected patients.5, 49 In 
summary, certain Acinetobacter spp., like A. calcoaceticus, A. johnsonii and A. guillouiae, 
seem to be widely distributed in the environment, while the natural habitat for A. baumannii 
and A. nosocomialis remains unclear. 
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To date the most prevalent clinically relevant species of the Acinetobacter genus is                 
A. baumannii, which possesses a high propensity to multi-drug resistance and is frequently 
associated with clinical outbreaks, which means infection of multiple patients in a hospital by 
the same strain. However, A. pittii and A. nosocomialis are also increasingly reported in 
association with outbreaks and antimicrobial resistance.13 
 
1.1.3 Acinetobacter species identification 
 
A wide range of molecular methods and semi-automated systems have been described to 
identify Acinetobacter isolates to the species level. These include for example, DNA-DNA 
hybridization, amplified fragment length polymorphism (AFLP), amplified ribosomal DNA 
restriction analysis (ARDRA), matrix-assisted laser desorption ionization-time-of-flight mass 
spectrometer (MALDI-TOF MS), semi-automated systems such as the Vitek2 system, 
amplification of the gyrase β-subunit gene (gyrB) by multiplex PCR and partial sequencing of 
the RNA-polymerase β-subunit gene (rpoB). 
 
The reference standard for Acinetobacter species identification is DNA-DNA 
hybridization.15 The technique is based on the determination of the melting temperature of 
hybridized complementary DNA strands. The DNA of a strain of interest and a reference 
strain are denatured. The reference DNA is radioactively labeled and mixed with an excess of 
the DNA of interest. Single-stranded DNA of both strains will bind complementary. These 
hybrid DNA-duplexes will be subsequently denatured (DNA-melting). The radioactive 
labeling allows tracing of the melting of heteroduplex DNA (double-stranded DNA which 
comprises single strands of the reference DNA and the DNA of interest). The more 
differences the DNA strands possess, the weaker the covalent bonds are, which results in a 
lower melting temperature. Therefore less related strains reveal a lower melting temperature 
than closely related strains. Although DNA-DNA hybridization is a suitable method for 
phylogenetic analysis and species identification, it is very laborious and thereby impractical 
for routine identification of Acinetobacter species.50 
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AFLP and ARDRA are based on restriction digest and amplification of DNA fragments.51, 52 
AFLP operates with a frequent cutting restriction enzyme (4 bp recognition site) and a rare 
cutting enzyme (usually 6 bp recognition site). After digestion, fragments which possess 
restriction sites of a frequent and a rare cutting enzyme are specifically amplified and 
radioactively or fluorescently labeled in two PCR reactions. In contrast, ARDRA is based on 
the amplification of species-specific ribosomal genes which are subsequently digested by 
multiple restriction enzymes. Species identification is performed by the visual analysis of 
PCR products (AFLP) or restriction patterns (ARDRA) of a strain of interest in comparison to 
reference strains. 
 
In routine laboratories the semi-automated MALDI-TOF MS (Bruker, Bremen, Germany) 
and Vitek2 (bioMérieux, Nürtingen, Germany) system are frequently used for Acinetobacter 
species identification.53, 54 MALDI-TOF MS is based on the crystallization and laser-mediated 
ionization of matrix-embedded samples and generates a species-specific mass spectrum, 
which can be compared to an online database.53 Vitek2 uses specifically designed cards which 
contain cavities either with dehydrated substrates for species identification or dehydrated 
antimicrobial agents for susceptibility testing. A standard inoculum of an isolate is prepared 
and added to the cavities of the card. The incubation, reading and interpretation of the card is 
automatically performed by a computer-based system which enables species identification 
within 5-8 hours. Phenotypically it is very hard to distinguish between the environmental 
species A. calcoaceticus and the clinically important organisms A. baumannii, A. pittii and      
A. nosocomialis.5 Thereby the latter species were combined in the “A. baumannii group”, 
whereas for all the four species the designation “A. calcoaceticus-A. baumannii complex” had 
been proposed.55 Based on their phenotypic similarity, the Vitek2 system is not suitable to 
differentiate among species of the “A. calcoaceticus-A. baumannii complex”.54 
A simple method to distinguish between these species is the gyrB multiplex PCR, recently 
established by Higgins et al.56, 57 The PCR is based on species-specific primer pairs that 
amplify partial regions of the gyrB gene, whereby specific amplicon sizes allow the 
differentiation between A. baumannii, A. calcoaceticus, A. nosocomialis and A. pittii. 
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Partial rpoB sequencing has been found to be a reliable tool for species identification in the 
genus Acinetobacter. La Scola et al. identified two variable regions within the gene which are 
flanked by conserved sequences.58 Sequencing of these 350-450 bp variable regions can be 
used to distinguish between Acinetobacter species. Based on its polymorphism, rpoB 
sequencing seems to be a more reliable method for species identification in Acinetobacter 
then sequencing of the 16S rRNA gene.58 
 
1.1.4 Acinetobacter baumannii: characteristics of a successful pathogen 
 
A. baumannii, also denoted as the “Gram-negative methicillin-resistant S. aureus (MRSA)”, is 
a hospital-acquired pathogen, which mainly infects patients with impaired host defenses. 
Therapy of A. baumannii infections can be difficult due to wide distribution of multi-drug 
resistance in combination with increasing rates of carbapenem resistance.5, 6 Accumulation of 
multiple resistance mechanisms in A. baumannii is based on great genome plasticity, the 
upregulation of innate resistance mechanisms and acquisition of foreign resistance genes.13 
Infections caused by A. baumannii include bloodstream infections, urinary tract infections, 
wound infections and meningitis, but particularly ventilator-associated pneumonia (VAP). 
Although community-acquired pneumonia has been reported in tropical climates,                   
A. baumannii is rarely isolated outside of the hospital environment.5 Risk factors for 
acquisition of A. baumannii infections are advanced age, immune suppression and severe 
underlying diseases, indwelling catheters, mechanical ventilation, invasive procedures, for 
example major surgeries and cardiac catheter examination, contact with patients that are 
infected or colonized with A. baumannii, extended hospital stay, particularly on intensive care 
units (ICU), and previous antimicrobial therapy.5, 6 The clinical impact of nosocomial            
A. baumannii infections is controversial. Although high mortality rates have been reported, 
this could be influenced by underlying diseases.59 A. baumannii is regarded as a low virulence 
pathogen, as it mainly affects immunocompromised patients. However, the organism 
possesses several attributes which support its ability to cause an infection. Recently identified 
virulence factors include lipopolysaccharides, capsular polysaccharides, phospholipases, the 
penicillin-binding protein 7/8, outer membrane vesicles (OMV) and an acinetobactin-
mediated iron acquisition system.60 
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An additional virulence factor is the outer membrane protein OmpA, which triggers 
adherence and invasion of epithelial cells and can induce apoptosis in host cells. The 
dissemination of OmpA into host cells is provided by OMVs.60 
 
Main reservoirs for A. baumannii in the hospital seem to be contaminated medical 
equipment, as well as colonized and infected patients.6 For example, A. baumannii can be 
easily spread through the air from the respiratory tracts of infected or colonized patients and 
contaminate the environment. Subsequent transmission of A. baumannii is supported by its 
prolonged viability outside of the human body. For example, the species can persist up to 4 
weeks on dry surfaces from where it can easily spread via the hands of the hospital staff, 
patients and visitors.61 Furthermore, A. baumannii possesses the ability to form biofilms on 
plastic and glass surfaces which might support colonization of medical devices like catheters 
and intubation equipment.62, 63 In addition, A. baumannii isolates can be resistant to 
disinfectants which results in dramatically reduced infection control opportunities.64, 65 
 
Long-term viability and transmission of A. baumannii in the hospital environment increases 
the likelihood of A. baumannii strains to colonize multiple patients. Consistently,                    
A. baumannii outbreaks have been reported in hospitals around the world which highlights the 
potential for A. baumannii to spread epidemically.59 This is also mirrored by the presence of 
several distinct A. baumannii clonal lineages. Several studies have demonstrated worldwide 
distribution of at least eight international clonal lineages (IC1 to IC8) of closely related         
A. baumannii isolates. Initially IC1, IC2 and IC3 were found to be distributed in European 
countries whereby these lineages were termed European clones I to III (EUI to EUIII).66 
Recent worldwide epidemiological studies identified global distribution of EUI to EUIII and 
revealed presence of additional A. baumannii clonal lineages, which were assigned as 
worldwide clonal lineages 1 to 8 (WW1 to WW8) with WW1 to WW3 corresponding to EUI 
to EUIII.67, 68 To avoid confusion the terms “European clonal lineages” and “worldwide 
clonal lineages” were subsequently converted into “international clonal lineages”. To date IC1 
and IC2 are the predominant lineages worldwide, while IC3 seems to be more prevalent in 
Europe.69 
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1.1.5 Molecular typing of A. baumannii 
 
Various molecular typing methods have been established to investigate the clonal relatedness 
of A. baumannii isolates, whereby the global epidemiology can be monitored and outbreaks 
can be analyzed. Frequently used typing methods include restriction-based pulsed-field gel 
electrophoresis (PFGE), amplification of repetitive extragenic palindromic regions (rep-PCR), 
multi-locus sequence typing (MLST) and sequence group typing. 
 
PFGE is considered to be the “gold-standard” of A. baumannii typing.70 The genomic DNA is 
restricted and fragments are separated on an agarose gel. Based on periodical changes of the 
electrical field during the electrophoresis, PFGE is suitable to separate high molecular nucleic 
acids of >10 kb, but this increases the gel running time compared to normal vertical gel 
electrophoresis. According to Tenover et al. isolates are regarded as epidemiologically related 
if the number of band differences in their restriction patterns is ≤ 6.71 
 
With regards to A. baumannii, MLST is based on the partial sequencing of seven 
chromosomal housekeeping genes. The method can be used for epidemiological studies, but is 
not suitable for fine-typing, for example to confirm clonal identity between different isolates. 
Two schemes exist, which can be used to distinguish between A. baumannii sequence types 
(ST); the Bartual (http://pubmlst.org/abaumannii/) and the Pasteur scheme (http://www. 
pasteur.fr/recherche/genopole/PF8/mlst/Abaumannii.html).72-74 Both schemes share three loci 
for sequence analysis; cpn60 (60 kDa chaperonin), gltA (citrate synthase) and recA 
(homologues recombination factor). In addition, the Bartual scheme includes sequences of 
gyrB (DNA gyrase β-subunit), gdhB (glucose dehydrogenase B), gpi (glucose-6-phosphate 
isomerase) and rpoD (RNA polymerase σ70 factor), while the Pasteur scheme includes 
sequences of fusA (elongation factor EF-G), pyrG (CTP synthase), rplB (50S ribosomal 
protein L2) and rpoB (RNA polymerase β-subunit). According to the websites, 770 and 493 
A. baumannii ST have been so far identified by the Bartual and Pasteur scheme, respectively. 
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rep-PCR based DiversiLab (bioMérieux, Nürtingen, Germany) is a semi-automated method, 
which has been recently used to identify IC1 to IC8.67 Primers amplify short repetitive 
extragenic palindromic regions which are spread in the Acinetobacter genome. rep-PCR 
products of the isolates of interest are loaded on a DNA chip and the software generates a 
virtual gel, a dendrogram and a similarity matrix. The results can be compared to the personal 
strain library. A similarity of > 95% indicates clonal relatedness, while a similarity of ≥ 98% 
indicates clonal identity.75 
Furthermore, clonal relatedness of A. baumannii isolates can be investigated by sequence 
group typing which is based on two allele-specific multiplex PCRs, which amplify the 
chromosomal genes blaOXA-51-like (β-lactamase), csuE (part of a pilus assembly system for 
biofilm formation) and ompA (outer membrane protein A).76 This method is suitable for the 
identification of IC1, IC2 and IC3. 
 
 
1.2 Mode of action and target sites of antimicrobial classes 
 
Target sites of antimicrobial compounds in the bacterial cell include the cell wall, cell 
membrane, DNA synthesis, RNA synthesis, protein synthesis and metabolism. The mode of 
action of an antimicrobial agent can be bacteriostatic or bactericidal. A bacteriostatic action 
inhibits bacterial replication, while a bactericidal action causes cell death. With regards to 
different target sites, the mode of action of antimicrobial classes will be explained below, with 
a special focus on β-lactams. As glycopeptides (e.g. vancomycin and teicoplanin), 
lincosamides (e.g. clindamycin) and oxazolidinones (e.g. linezolid) are inactive against Gram-
negative bacteria, these classes are not included. 
 
1.2.1 Overview of antimicrobial classes active against Gram-negative bacteria 
 
An overview of the target sites of antimicrobial agents in Gram-negative bacteria is given in 
Figure 2. Cell wall synthesis is affected by β-lactams, which inhibit peptidoglycan cross-
linking which results in cell death (this is further explained in 1.2.2). 
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As cell wall synthesis is only active in growing cells, the bactericidal effect of β-lactams does 
not impair cells in stationary phase. In contrast to β-lactams, polymyxins (e.g. polymyxin E 
(colistin) and polymyxin B) possess a high affinity for negatively charged surfaces, for 
example the lipopolysaccharide (LPS) layer and the outer membrane (see Figure 5). 
Interaction of polymyxins with these structures leads to their perforation, which results in cell 
death. It should be noted that polymyxins can also affect cell membranes of human cells and 
can cause nephrotoxicity.77 
The RNA- and DNA synthesis are affected by rifampicin (RNA synthesis), quinolones 
(RNA- and DNA synthesis) and folate metabolism antagonists, like sulfonamides and 
trimethoprim (folate metabolism and consequently DNA synthesis). Rifampicin inhibits the 
transcription initiation by binding to the active site of the DNA-dependent RNA polymerase.  
In contrast, quinolones (e.g. nalidixic acid) target the bacterial DNA gyrase (topoisomerase II) 
and topoisomerase IV which are needed during DNA replication, transcription and cell 
division to relax negative supercoilings and decatenation. By stabilizing topoisomerase-DNA 
complexes quinolones are able to inhibit these cellular processes. Fluoroquinolones            
(e.g. ciprofloxacin) possess a fluorine atom at the C6 carbon which increases their affinity to 
topoisomerases. 
 
DNA
mRNA protein
β-lactams
aminoglycosides
chloramphenicol
tetra- / glycylcyclines
macrolides
polymyxins
rifampicin
quinolones
outer membrane
inner membrane
quinolones
replicated
DNA 
folate
metabolism
trimethoprim
sulfonamides
 
Figure 2: Target sites of antimicrobial agents in Gram-negative bacteria. Inhibition of cellular 
processes or products (cell wall) is indicated with red bars. Perforation of cell wall and outer 
membrane by polymyxins is indicated by dashed lines. 
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Sulfonamides (e.g. sulfamethoxazole) and trimethoprim act on the bacterial folate metabolism 
at two different positions. While sulfonamides are active against the dihydropteroic            
acid-synthetase at an earlier stage of the pathway, trimethoprim inhibits the diahydrofolic          
acid-reductase at the end of the pathway. To block the whole metabolism pathway 
sulfonamides are often combined with trimethoprim, which results in a bactericidal effect. 
The natural product of the pathway is tetrahydrofolate (THF) which, in form of formyl-THF, 
is a cofactor during purine synthesis. Therefore inhibition of THF synthesis subsequently 
inhibits DNA synthesis. 
Protein synthesis is targeted by aminoglycosides (e.g. amikacin and gentamicin), 
chloramphenicol, tetracyclines (e.g. tetracycline and doxycycline) and their structural 
derivatives gycylcylines (e.g. tigecycline), as well as macrolides (e.g. erythromycin). The 
bacterial ribosome comprises of the 30S and 50S subunit, which are both targets for 
antimicrobial agents. For example, aminoglycosides act on the translation and elongation in 
protein biosynthesis via irreversible binding to the 30S subunit of the ribosome which causes 
misreading of the mRNA and generates non-functional proteins. These nonsense proteins can 
be integrated into the cell membrane, leading to reduced stability and cell lysis. Tetracyclines 
and glycylcylines are also active against the 30S ribosomal subunit, but in contrast to 
aminoglycosides they block the tRNA binding site whereby attachment of the aminoacyl-
tRNA to the mRNA is prevented and translational elongation is inhibited. The 50S ribosomal 
subunit is targeted by chloramphenicol and macrolides, which prevent translocation of the 
aminoacyl-tRNA within the ribosome, whereby the translation is terminated. 
 
1.2.2 Detailed focus on β-lactams 
 
Structural basis of the class of β-lactams is the four-membered β-lactam ring (Figure 3). With 
regards to additional structural components β-lactams are divided into four subclasses; 
penicillins, cephalosporins, monobactams and carbapenems. Furthermore, penicillins and 
cephalosporins can be subdivided into four groups, respectively. The subclass of penicillins 
includes penicillin G and derivatives, isoxazolylpenicillins, aminobenzylpenicillins and 
acylaminopenicillins, which are distinguished on the basis of structural differences. 
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Figure 3: Structure of the β-lactam ring. 
 
In contrast, cephalosporins are divided into group 1 to 4, based on their mode of action. The 
activity against Gram-negative bacteria is increased from group 1 to 4, while the activity 
against Gram-positive bacteria can be decreased. Groups 3 and 4 possess a broad spectrum of 
activity against Gram-negative species and group 4 additionally exhibits a broad spectrum 
against Gram-positive species. Therefore agents of these groups are also termed            
extended-spectrum cephalosporins. In contrast to penicillins and cephalosporins, the 
monobactam aztreonam is inactive against Gram-positive bacteria. 
 
As this dissertation focuses on carbapenem resistance in Acinetobacter spp., the carbapenems 
will be explained in more detail. The first naturally occuring carbapenem, thienamycin 
produced by Streptomyces cattleya, was identified in 1976 (Figure 4).78 To date four         
semi-synthetic derivatives of thienamycin are used in the treatment of bacterial infections; 
imipenem, meropenem, doripenem and ertapenem (Figure 4). 
 
The bactericidal action of carbapenems is independent of the concentration, but depends on 
the time the minimal inhibitory concentration is exceeded. Resorption of carbapenems in the 
intestinal tract is inadequate. Therefore the application of carbapenems occurs parenterally 
(intervenously), which is the reason why these agents are mainly used in the hospital. In 
contrast to other carbapenems, imipenem is hydrolyzed by the dehydropeptidase I which is 
produced in the kidneys. To ensure a stable concentration of the substance in the body, 
imipenem has to be applied in combination with cilastatin which reversibly inhibits the 
dehydropeptidase I. 
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Figure 4: Structure of the β-lactam subclass of carbapenems. 
 
The addition of a methylgroup at C1 provides stability of the other carbapenem compounds 
against the renal dehydropeptidase I, wherefore the combination with cilastatin is 
unnecessary. MDR Gram-negative bacteria, including A. baumannii, often retain 
susceptibility against carbapenems, which is the reason why this subclass of β-lactams is used 
as the drugs of choice to treat infections with these pathogens. 
 
Target sites and mode of action of β-lactams 
 
β-lactams affect the cell wall synthesis in Gram-negative and Gram-positive bacteria. In 
Gram-negative bacteria the cell wall consists of 2-5 cross-linked peptidoglycan layers 
(murein) and an outer membrane, which contains phospholipids, proteins, channel-forming 
porins and lipopolysaccharides (LPS) (Figure 5). The outer membrane is linked to the 
peptidoglycan via lipoproteins. 
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Figure 5: Composition of the Gram-negative cell wall; adapted79. 
 
The target sites of β-lactams are transpeptidases and carboxypeptidases, enzymes which are 
involved in murein synthesis. The peptidoglycan layers are based on long chains of the sugar 
derivatives N-acetyl glucosamine and N-acetyl muramic acid (Figure 6). The N-acetyl 
muramic acids are further linked to pentapeptides which are essential for the cross-linking of 
two peptidoglycan strands.80 These pentapeptides terminate in two D-alanine residues. 
 
In Gram-negative bacteria transpeptidases catalyse a bond between the peptide chains of two 
peptidoglycan strands by connecting the penultimate D-alanine with meso-diamino pimelic 
acid. The terminal D-alanine residues are cleaved by carboxypeptidases (Figure 6). Although 
β-lactams target both enzymes, the inhibition of carboxypeptidases is negligible. The 
bactericidal effect of β-lactams is mainly based on the inhibition of transpeptidases. The 
ability of transpeptidases to bind β-lactam agents has led to the alternative term “penicillin 
binding proteins” (PBPs).80 Reaction of the transpeptidase with the β-lactam results in a 
covalent bond of a serine residue in the active centre of the transpeptidase with the β-lactam 
ring (acyl-enzyme complex), which obstructs the cross-linking reaction. Based on poorly 
cross-linked murein the cell wall is unable to resist the turgor of the cell, which leads to cell 
lysis. 
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Figure 6: Peptidoglycan crosslinking in Gram-negative bacteria; adapted79. Transpeptidase- and 
carboxypeptidase-mediated reactions are indicated with an arrowhead and scissors, respectively. G, N-
acetyl glucosamine; M, N-acetyl muramic acid 
 
 
1.3 Antimicrobial susceptibility testing 
 
Antimicrobial susceptibility of bacterial isolates is determined on the basis of the minimal 
inhibitory concentration (MIC), which defines the lowest concentration of a drug (mg/L) at 
which bacterial growth is inhibited. The susceptibility data are compared to given clinical 
breakpoints, which allow interpretation of an isolate as susceptible (S), intermediate (I) or 
resistant (R) to a certain drug. The breakpoints are established by official committees of 
various institutions, for example the Clinical and Laboratory Standards Institute (CLSI) and 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST).81 The 
susceptibility of a bacterial isolate to antimicrobial agents can give suggestions for 
appropriate treatment options. For example, if an isolate is susceptible to a certain drug, this 
agent possesses a high activity against the isolate and might be considered for therapy. In 
contrast, resistance to a certain agent implies low activity of the drug and indicates potential 
treatment failure. The intermediate level implies uncertainty of a treatment success. For 
example, the drug might retain a therapeutic effect if a high dosage can be used or if the drug 
can be concentrated at the site of infection. However, depending on the institution which set 
the breakpoints, the intermediate level might be missing. 
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Standardization of susceptibility testing methods has been established by various institutions, 
including CLSI and EUCAST.82, 83 Frequently used methods are for example the epsilometer 
test (Etest), disc diffusion, agar dilution and microbroth dilution. Etest, disc diffusion and agar 
dilution are performed on agar plates, while microbroth dilution is performed in microtiter 
plates which contain 96 cavities. The type of solid and liquid media can vary depending on 
the institution that established the guidelines, but commonly Mueller-Hinton media are 
recommended.  Single colonies of a freshly subcultured strain are used to prepare the standard 
inoculum for the susceptibility test. Using a cotton swab colonies are taken from the plate and 
suspended in 0.9% NaCl solution to achieve a cell density of McFarland 0.5 which equals      
1-1.5 x 108 cells. To perform Etest or disc diffusion, the swab is used to inoculate the testing 
agar plate. Afterwards an Etest strip or an antibiotic disc is placed on top of the inoculated 
agar and incubated for 16-18 (-24) hours. 
 
Etest strips contain a gradient of an antimicrobial agent, which diffuses into the agar where it 
can inhibit bacterial growth. After overnight incubation an elliptic zone of inhibition might be 
visible which allows MIC determination. If the zone of inhibition is missing, the MIC is 
interpreted as higher than the maximum concentration of the agent on the strip. For example, 
the maximum concentration of imipenem and meropenem Etest strips is 32 mg/L, whereby 
the lack of an inhibition zone would be interpreted as an MIC of >32 mg/L. In contrast to an 
antimicrobial gradient, antibiotic discs which are used for disc diffusion contain a fixed 
concentration. The antimicrobial agent diffuses into the agar and can inhibit growth of the 
surrounding cells during overnight incubation. The susceptibility is interpreted on the basis of 
the diameter of this zone of inhibition which corresponds to the MIC. 
 
In contrast to Etest and disc diffusion, the agar dilution plates contain serial dilutions of a 
certain drug. A 1:100 dilution of the standard cell suspension is used to inoculate the agar 
plate. The inoculation can be performed semi-automatically, which allows investigation of 
multiple isolates simultaneously. After overnight incubation the MIC values can be 
determined. 
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Microbroth dilution allows susceptibility testing of multiple antimicrobial agents on one 
microtiter plate. The cavities of the plate contain different concentrations of antimicrobial 
agents, which are present as either liquid or freeze-dried. The standard inoculum is diluted in 
liquid medium, according to the manufacturer´s instruction, and a defined volume of the 
dilution is supplied into the cavities. After overnight incubation the MIC values can be 
determined. 
 
 
1.4 Antimicrobial resistance in A. baumannii 
 
Bacterial defense against naturally occurring antibiotics, like penicillin produced by some 
fungi or Actinobacteria, is an ancient mechanism. However, excessive usage of antimicrobial 
agents during the last decades has supported the evolution and the spread of resistance 
mechanisms. Resistance can be intrinsic, based on innate mechanisms which are present in 
every organism of a species, or acquired. Resistance mechanisms in Gram-negative bacteria 
include enzymatic hydrolysis or modification of the drug, mutations in the drug target, 
reduced permeability, active efflux of the drug, ribosomal mutations or modifications, 
lipopolysaccharide (LPS) mutations and rarely metabolic bypass pathways.84 
 
1.4.1 Distribution of antimicrobial resistance determinants 
 
The spread of antimicrobial resistance determinants in A. baumannii is supported by the 
transfer of plasmids, or mobile genetic elements, like insertion sequences (IS elements) and 
transposons. Furthermore, genetic structures like integrons and resistance islands contribute to 
the accumulation of multiple resistance genes. Plasmids can harbor IS elements, transposons 
and integrons which further highlights the potential for rapid spread of antimicrobial 
resistance genes. 
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Insertion sequences 
 
Insertion sequences are small genetic elements of approximately 0.8 to 2.5 kb. They encode 
one or more transposase genes (tnp) which are flanked by two inverted repeats and mediate 
transposition of the IS element (Figure 7).85 Transposition can either generate a copy or excise 
the full-length IS element which will be inserted in the same parental DNA or a different one, 
for example a plasmid. Insertion of the IS element at a new position leads to the duplication of 
the insertion- or target site presented by two direct repeats. 
 
tnp IRIR
-35/-10 -35
DR DR
 
Figure 7: Schematic composition of an insertion sequence. Possible promoter regions provided for 
adjacent genes are indicated with thin arrows (-35/-10: full-length promoter; -35: partial promoter). 
tnp, transposase gene; IR, inverted repeat; DR, direct repeat 
 
Insertion sequences often contain strong promoter sequences which can confer overexpression 
of adjacent antimicrobial resistance genes (Figure 7). Furthermore, IS elements often provide 
-35 regions which can generate a hybrid promoter in the presence of a downstream located     
-10 region. A common IS element in A. baumannii is ISAba1 (insertion sequence 
Acinetobacter baumannii 1) which can be found in multiple copies on A. baumannii genomes 
and is often associated with β-lactam resistance genes.86 
 
Transposons 
 
Transposons are large mobile genetic structures. Similar to IS elements they harbor 
transposase genes and are flanked by inverted repeats (Figure 8). In addition, transposons can 
contain other mobile genetic structures (e.g. integrons (Figure 9)) and often encode additional 
genes (e.g. resistance genes and chaperone genes). The flanking inverted repeats are 
commonly part of IS elements. If these are identical or closely related to each other the 
genetic structure is called composite transposon. 
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Comparable to IS elements, transposition results in target site duplication, indicated by two 
direct repeat regions (DR) at both ends of the transposon (Figure 8). 
 
IRIR tnp
DR
IS element
IRIR tnp
DR
IS element
 
Figure 8: Schematic composition of a transposon. Flanking IS elements are indicated with boxes. The 
middle part contains a variable number of structural and resistance genes, which are indicated by 
coloured arrowheads. tnp, transposase gene; IR, inverted repeat; DR, direct repeat 
 
In A. baumannii β-lactamases of the acquired OXA-23 subclass are frequently encoded on 
transposons, for example Tn2006, a composite transposon which is flanked by two copies of 
ISAba1.68 
 
Integrons 
 
Integrons vary in size depending on their genetic composition (Figure 9) and are often part of 
large transposons. These elements encode a site-specific integrase which conducts 
accumulation of resistance genes at the attI1 recombination site.85 The integrase gene (intI) 
provides the promoter (Pc) for downstream located cassettes which can contain multiple 
resistance genes. These gene cassettes are separated by small terminator sites with possible 
stem-loop structures (59-base-pair elements (59 be) or attC). 
 
cassette 2 cassette 1 
59 be 59 be
Pc
attI1intI
 
Figure 9: Schematic composition of an integron. The promoter Pc is indicated with a thin arrow. Gene 
cassettes are highlighted in grey, while resistance genes are not separately illustrated. intI, integrase 
gene; attI1, recombination site; 59 be, 59-base-pair element 
Introduction 
 
24 
 
Integrons are widespread genetic structures in MDR A. baumannii where they are frequently 
associated with aminoglycoside, chloramphenicol and sulfonamide resistance.87 
 
Resistance islands 
 
Probably the largest mobile elements in A. baumannii are the recently identified resistance 
islands. These genetic structures show diverse compositions based on multiple transposons, 
integrons and IS elements, as well as stress response proteins, proteins involved in 
translocation processes, chromosomal DNA and putative open reading frames (ORF). To date 
the largest resistance island identified in A. baumannii, AbaR25, is 121.7 kb in size and 
harbors 141 ORFs of which seven encode antibiotic resistance genes.88 In contrast, AbaR1 is 
86 kb large and carries 88 ORFs, including 45 resistance genes.89 Resistance islands in          
A. baumannii seem to have similar integration sites in chromosomal genes, like comM 
(encodes an ATPase) or pho (encodes a phosphatase).90 
 
Plasmids 
 
Plasmids are self-replicating, circular DNA molecules of 1 to >100 kb which bacteria can take 
up via conjugation from different species of their own genus or other related genera. 
Conjugation is based on the assembly and disassembly of a filamentous pilus, providing close 
contact of two bacterial cells, which is needed for the generation of a direct cell to cell 
contact. The respective channel spans the cytoplasmic membrane and the outer membrane and 
provides transfer of the replicated plasmid from the donor to the recipient cell.                   
Self-transmissible or conjugative plasmids harbor all genes which are necessary for channel 
formation, plasmid replication and transfer. Plasmids which lack the genes for the channel 
formation are unable to trigger their transfer, but can be mobilized in the presence of a 
conjugative plasmid. Plasmids often encode several resistance genes, which can be part of 
transposons and integrons. If transposons and IS elements are part of the plasmid they might 
be transposed from the plasmid to the chromosome, providing a high potential for bacterial 
genome plasticity and further distribution of resistance determinants. In A. baumannii the 
characterization of plasmids is performed by replicon typing, recently described by          
Bertini et al.91 The six established multiplex PCRs distinguish between 19 different replicase 
genes of widespread plasmids in A. baumannii. 
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1.4.2 Resistance of A. baumannii to multiple antimicrobial classes 
 
A. baumannii exhibits a high propensity to multi-drug resistance. To illustrate the reduction of 
treatment options in A. baumannii, the variety of resistance mechanisms against 
aminoglycosides, chloramphenicol, macrolides, tetracyclines and glycylcyclines, 
fluoroquinolones, polymyxins (colistin), rifampicin and folate antagonists will be 
summarized. 
 
Drug-modifying enzymes, target site mutations and drug efflux play important roles in the 
development of antimicrobial resistance in A. baumannii. For example, resistance to 
aminoglycosides is commonly mediated by drug-modifying enzymes including 
phosphotransferases (e.g. APH(3´)), acetyltransferases (e.g. AAC(6´)I-ad) and 
adenyltransferases (e.g. AAD(3´´)-Ia).62, 92, 93 Another aminoglycoside-resistance determinant 
in Acinetobacter spp. is ArmA, an RNA-methylase that modifies 16S rRNA and reduces 
affinity for aminoglycosides to bind to the 30S ribosomal subunit.62 Resistance to 
chloramphenicol is frequently conferred by plasmid-encoded proteins, including a          
drug-modifying acetyltransferase (cat gene) or an efflux pump (cmlA gene). Additional efflux 
pumps associated with chloramphenicol resistance are CraA (chloramphenicol specific 
pump), the small multidrug resistant (SMR) pump AbeS and the multi antimicrobial extrusion 
(MATE) pump AbeM.62 Macrolide resistance has been found to be associated with resistance 
genes mph (encodes a drug-modifying enzyme) and mel2 (encodes an efflux pump).94 In 
contrast, tetracycline resistance can be mediated by efflux pumps of the multi facilitator 
superfamily (MFS) (TetA and TetB) and ribosomal protection proteins (TetM and TetO). 
Ribosomal protection proteins are cytoplasmatic proteins which are assumed to be related to 
elongation factors and are able to release tetracycline from the ribosome.95 Although MDR   
A. baumannii often retain susceptibility to the glycylcycline tigecycline, efflux-mediated 
resistance via RND pumps is increasingly reported.62 Common resistance mechanism in       
A. baumannii also include mutations in the chromosomal DNA gyrase genes gyrA and gyrB 
or the topoisomerase IV genes parC and parE, which can lower the affinity of 
fluoroquinolones to the topoisomerase-DNA complex. Ciprofloxacin-resistant isolates often 
harbor mutations in gyrA (Ser-86-Leu substitution) and parC (Ser-80-Leu substitution), but 
efflux has also been reported.62 
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Plasmid-mediated fluoroquinolone-resistance determinants, as found in Enterobacteriaceae 
(e.g. qnrA) have so far not been detected in A. baumannii. Furthermore, reduced colistin 
susceptibility has been proposed to be associated with LPS modification and increased 
expression of the two-component system PmrAB which might have to be coupled with amino 
acid changes in PmrB.96 Furthermore, total loss of the LPS via mutations in the lipid A 
synthesis genes lpxA, lpxC or lpxD was associated with decreased colistin susceptibility in a 
laboratory mutant.96 Resistance to rifampicin in A. baumannii can be mediated by mutations 
in the chromosomally encoded RNA polymerase β-subunit gene (rpoB) that alter the amino 
acid composition of the active centre of the polymerase or an acquired rifampicin ADP-
ribosylating transferase (encoded by arr-2) which inactivates rifampicin by ribosylation.62 
Widespread resistance to sulfonamides and trimethoprim in A. baumannii is conferred by 
the generation of isoenzymes which exhibit reduced affinity to these compounds and are 
usually encoded on plasmids (sul or dfr genes).62 
 
In addition to the above mentioned mechanisms, a MDR phenotype in A. baumannii can be 
based on overexpression of the common resistance-nodulation-cell division (RND) efflux 
pump family (see 1.4.3), which typically exhibits a broad substrate spectrum including many 
antimicrobial classes.97 For example, the A. baumannii efflux pump systems (Ade) ABC and 
IJK have been found to be associated with resistance to aminoglycosides (AdeABC),              
β-lactams, chloramphenicol, fluoroquinolones, lincosamines (AdeIJK), macrolides 
(AdeABC), tetracyclines, tigecycline, and trimethoprim (AdeABC).98 Furthermore, 
overexpression of AdeFGH has been reported to confer resistance to chloramphenicol, 
clindamycin (lincosamines), fluoroquinolones and trimethoprim, as well as reduced 
susceptibility to tetracycline, tigecycline and sulfamethoxazol.98 
 
The spread of resistance determinants and development of novel resistance mechanisms, has 
led to global emergence of MDR A. baumannii. Although carbapenems are used as the drugs 
of choice to treat infections with these pathogens, carbapenem resistance in A. baumannii is 
increasingly reported.99 Mechanisms which contribute to β-lactam resistance, particularly 
carbapenem resistance, will be explained in the following section. 
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1.4.3 Resistance of A. baumannii to β-lactams 
 
The main mechanism for β-lactam resistance in Acinetobacter spp., particularly in                  
A. baumannii, is the production of drug-hydrolyzing enzymes (β-lactamases).100 Via    
channel-forming proteins (porins), which span the outer membrane, β-lactam agents from the 
surrounding medium enter the Gram-negative cell and reach the periplasm, the acting site of 
the β-lactamases. 
 
Enzyme-mediated β-lactam resistance 
 
β-lactamases inactivate β-lactam agents by hydrolysis of the amide bond in the β-lactam ring. 
According to their mode of action, β-lactamases are divided into serine- and metallo-β-
lactamases which either need a serine residue or one or two zinc ions in their active centre.80 
 
 Enzymatic hydrolysis of β-lactam agents 
 
The reaction of serine-β-lactamases is based on acylation and deacylation.101 The      
hydroxyl-group of the serine residue in the active centre of the β-lactamase reacts with the 
carboxyl-carbon of the β-lactam ring, whereby the carbon-nitrogen bond is opened and an 
acyl-enzyme intermediate is generated. This intermediate reacts with a water molecule which 
results in regeneration of the hydroxyl-group in the active serine residue of the β-lactamase 
and release of the inactivated β-lactam agent. To overcome the problem of widespread             
β-lactamase mediated resistance, β-lactam derivatives like tazobactam, sulbactam and 
clavulanic acid have been generated. These β-lactamase inhibitors irreversibly bind to the 
enzyme, preventing its interaction with the β-lactam and therefore leading to inactivation of 
the β-lactamase. However not all serine-β-lactamases are significantly affected by these 
inhibitors. Moreover, extensive use of β-lactams during the last decades has supported the 
evolution and selection of more effective enzymes which are active against an extended 
spectrum of substrates (extended-spectrum β-lactamases (ESBLs)), including            
extended-spectrum cephalosporins and monobactams.80 
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In contrast to serine-β-lactamases, metalloenzymes harbor one (mononuclear) or two 
(binuclear) zinc ions in their active centre. As a consequence these enzymes are inactivated by 
chelators, like EDTA, but are not affected by β-lactamase inhibitors. Metallo-β-lactamases 
are divided into three subclasses; B1 (e.g. VIM-4 from Pseudomonas aeruginosa), B2         
(e.g. CphA from Aeromonas spp.) and B3 (e.g. L1 from Stenotrophomonas maltophilia).101 
Enzymes of subclasses B1 and B3 are active with two zinc ions in their active centre and 
exhibit a broad substrate spectrum which includes penicillins, cephalosporins and 
carbapenems. In contrast, B2 enzymes possess a narrow substrate spectrum, including 
carbapenems, and need one zinc ion for proper activity. The catalytic mechanism of      
metallo-β-lactamases is not fully understood yet. However, it is proposed that the hydrolysis 
of the amide bond in the β-lactam ring is generated via the attack of either a hydroxide ion 
(subclasses B1 and B3) or a water molecule (subclass B2) in the active site of the enzyme on 
the carboxyl-carbon of the β-lactam ring.101 Zinc ions are proposed to interact with functional 
groups of the β-lactam agent and stabilize the hydroxide ion as well as anionic intermediates 
which are generated during hydrolysis. 
 
 Classification of β-lactamases 
 
β-lactamases are generally classified by two different schemes which have been proposed by 
Ambler et al. and Bush et al.102, 103 Bush et al. analysed functional characteristics and the 
molecular structure of β-lactamases and identified 4 classes (1 to 4), with the second class 
being further divided into eight subclasses. This classification gives additional information 
about the substrate spectrum and inhibitor susceptibilities. In contrast Ambler et al. based 
their classification scheme on the amino acid sequences to analyse clonal relatedness of           
β-lactamases. The Ambler classification contains four classes (A to D), with classes A, C and 
D containing serine-β-lactamases, while metallo-β-lactamases are represented by class B. An 
overview of the different subclasses of β-lactamases in Acinetobacter spp. according to the 
Ambler classification is given in Table 2 and Table 3. 
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β-lactamase (bla) genes can be encoded on the chromosome or on plasmids and are 
widespread in the genus Acinetobacter.67, 104, 105 A. baumannii harbors two innate, 
chromosomally encoded β-lactamases; AmpC and OXA-51-like. In addition numerous 
acquired β-lactamases have been recently identified in A. baumannii and other Acinetobacter 
spp.62 
 
 β-lactamases with no activity against carbapenems 
 
A wide range of β-lactamases without carbapenem-hydrolysing activity have been reported in 
A. baumannii, including class A, class C and class D enzymes (Table 2). Class A                     
β-lactamases without carbapenem-hydrolysing activity in A. baumannii include several 
narrow-spectrum and extended-spectrum cephalosporinases. The class C cephalosporinase 
AmpC is intrinsic to A. baumannii but is usually expressed at low level.106 IS-mediated 
overexpression of the chromosomal AmpC or acquisition of the extended-spectrum       
AmpC-type β-lactamase (ESAC) can affect susceptibility against penicillins and 
cephalosporins. In addition to class A and class C, class D β-lactamases without     
carbapenem-hydrolysing activity from P. aeruginosa have been described in A. baumannii 
(Table 2).107 
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Table 2: β-lactamases without carbapenem-hydrolysing activity in A. baumannii. 
Ambler 
class 
Substrate Enzyme Reference 
A 
cephalosporins 
narrow spectrum: 
TEM-1, TEM-2, CARB-5, SCO-1 
Poirel et al.62 
cephalosporins 
with extended 
spectrum and 
aztreonam 
extended spectrum: 
PER-1, PER-2, PER-7, VEB-1, CTX-M-2, 
CTX-M-15, CTX-M-43, TEM-92, TEM-116, 
SHV-5, SHV-12, RTG-4 
Poirel et al.62, Potron et al.108  
C 
 
penicillins and 
cephalosporins 
AmpC-type (intrinsic) Jacoby et al.106 
penicillins and 
cephalosporins 
with extended 
spectrum 
extended spectrum: 
ESAC 
Poirel et al.62  
D 
penicillins and 
cephalosporins 
narrow spectrum:  
OXA-20, OXA-21, OXA-37 
Roca et al.107 
AmpC, ampicillinase; CARB, carbenicillinase; CTX-M, cefotaximase from Munich, Germany; ESAC, 
extended-spectrum AmpC-type β-lactamase; OXA, oxacillinase; PER, Pseudomonas extended resistant; RTG, 
enzyme with conserved RTG (arginine, threonine, glycine) triad; SCO, carbenicillinase from E. coli; SHV, 
sulfhydryl variable (variable susceptibility to sulfhydryl inhibitors); TEM, Temoniera (name of the patient the 
enzyme was first isolated from); VEB, Vietnam extended-spectrum β-lactamase 
 
 Carbapenem-hydrolysing β-lactamases 
 
Carbapenem-hydrolysing enzymes identified in Acinetobacter spp., mainly A. baumannii, 
include class A β-lactamases, class B metallo-β-lactamases and class D β-lactamases        
(Table 3). Carbapenem-hydrolysing class A and B β-lactamases previously identified in          
A. baumannii include carbapenemases from Klebsiella pneumoniae (KPC),                  
extended-spectrum GES-type cephalosporinases, as well as several B1 metalloenzymes of the 
IMP-, NDM-, SIM- and VIM-type (Table 3).107 
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Table 3: Carbapenem-hydrolysing β-lactamases in A. baumannii. 
Ambler 
class 
Additional 
substrates 
Representative enzyme Reference 
A 
- KPC-2 to KPC-4, KPC-10  Poirel et al.62 
cephalosporins and 
aztreonam 
extended spectrum: 
GES-11,  GES-14, GES-22  
Karah et al.68, Cicek et al.109  
B 
most β-lactams, 
except aztreonam 
IMP-1, IMP-2, IMP-5, IMP-6, 
IMP-11, SIM-1, NDM-1, NDM-2 
VIM-1, VIM-2 
Poirel et al.62 
D penicillins 
OXA subclasses:  
OXA-51-like (intrinsic), OXA-23-
like, OXA-40-like, OXA-58-like, 
OXA-143-like, OXA-235-like 
Poirel et al.104, Higgins et al. 97 
GES, Guinea extended-spectrum β-lactamase; IMP, imipenemase; KPC, Klebsiella pneumoniae carbapenemase; 
NDM, New Delhi metallo-β-lactamase; OXA, oxacillinase (carbapenem-hydrolysing class D β-lactamase 
(CHDL)); SIM, Seoul imipenemase; VIM, Verona integron-encoded metallo-β-lactamase 
 
However, class D β-lactamases with carbapenem-hydrolysing activity are the most frequently 
detected carbapenem-resistance determinants in A. baumannii. The abbreviation OXA might 
be confusing, as it is also used for class D β-lactamases which lack carbapenem-hydrolysing 
activity (see Table 2). The class D β-lactamases are a large group of enzymes which were 
designated oxacillinases (OXA) according to their preferential hydrolysis of oxacillin. 
Depending upon the substrate spectrum, the group can be subdivided into three subclasses. 
The first two subclasses include narrow spectrum oxacillinases (see Table 2) and       
extended-spectrum oxacillinases (ES-OXA) which are inactive against carbapenems and are 
prevalent in P. aeruginosa. The third subclass is represented by carbapenem-hydrolysing 
class D β-lactamases (CHDL), which are widespread in the genus Acinetobacter, particularly               
A. baumannii. To date, six different subclasses of CHDL have been identified in                    
A. baumannii; the intrinsic OXA-51-like and the acquired OXA-23-like, OXA-40-like,      
OXA-58-like, OXA-143-like and OXA-235 (see 2.4.2).110, 111 In contrast to OXAs which lack 
carbapenem-hydrolysing activity (see Table 2), these enzymes are not inhibited by clavulanic 
acid, sulbactam and tazobactam. 
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It has been proposed that the acquired blaOXA-23-like in Acinetobacter spp. derived from              
A. radioresistens to which the gene is intrinsic.112 The origin of the other acquired OXA 
subclasses is unknown. The subclass-specific numbers (e.g. OXA-51-like) represent the first 
identified enzyme of the respective group. Generally, OXA-specific numbers are assigned by 
the Lahey β-lactamase database (http://www.lahey.org/Studies/). To show that each subclass 
possesses multiple amino acid variants each subclass notation includes the term “-like”. 
Representative enzymes of different OXA subclasses show amino acid identities between 
49% (OXA-23 and OXA-58) and 88% (OXA-40 and OXA-143). Although OXAs are weak 
carbapenem hydrolysers they can confer resistance to carbapenems in the presence of 
additional resistance determinants and when expression of the bla gene is increased. This can 
be mediated by strong promoters which are mainly provided by IS elements (see 1.4.1).104 
However, OXA-40-like and OXA-143-like are usually not associated with these genetic 
structures. Table 4 summarizes IS elements which have already been detected in association 
with blaOXA in A. baumannii. 
 
Table 4: blaOXA associated IS elements in A. baumannii. 
Subclass Associated IS elements Reference 
OXA-51-like ISAba1, ISAba9, ISAba825 
Roca et al.107, Lopes et al.113 and 
Poirel et al.114 
OXA-23-like ISAba1, ISAba4, ISAba10 
OXA-58-like 
ISAba1, ISAba2, ISAba3, ISAba8, 
ISAba125, ISAba825, IS18, IS26 
OXA-235-like ISAba1 Higgins et al.111 
 
The diversity of OXAs and their association with mobile genetic structures in A. baumannii 
might indicate further spread in non-baumannii Acinetobacter species which could also play 
an important role in clinical settings in the future. 
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Non-enzymatic β-lactam resistance 
 
β-lactam resistance in A. baumannii might be enhanced by additional resistance mechanisms. 
Characteristic for Gram-negative bacteria are channel-forming proteins (porins) which span 
the outer-membrane and provide material exchange between the cell and the surrounding 
medium but also allow β-lactams to enter the periplasm. Compared to other Gram-negative 
bacteria A. baumannii possesses a naturally low permeability, which is based on low porin 
expression and diffusion rates.115 Therefore reduced expression or total loss of one of these 
porins can be associated with β-lactam resistance. For example, loss of the porins CarO, the 
43 kDa OMP (a homologue of the P. aeruginosa porin OprD) and the 33-36 kD OMP has 
been suggested to be associated with imipenem resistance in clinical A. baumannii isolates.5, 
116, 117 
 
Several efflux systems have been identified in Acinetobacter spp. which actively extrude 
antimicrobial agents and toxic compounds out of the cell. As mentioned before (see 1.4.2) 
RND pumps are common efflux systems in the genus Acinetobacter. These pumps are 
compromised of three parts (an outer membrane pore, an inner membrane pump and a 
membrane fusion protein) and translocate their substrates out of the cell coupled with proton 
transport (antiporter). While AdeABC and AdeIJK can be involved in β-lactam resistance, 
including extended-spectrum cephalosporins (AdeABC) and aztreonam (AdeIJK), AdeFGH 
seems to have no effect on β-lactam susceptibility.98  In the presence of                   
carbapenem-hydrolysing OXA, overexpression of AdeABC has been proposed to enhance 
meropenem resistance in A. baumannii.118 However, the effect on other carbapenems remains 
unclear. 
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2. Results 
 
2.1 Molecular characterization of blaNDM-1 in an Acinetobacter baumannii 
strain isolated in Germany in 2007 
 
The New Delhi metallo-β-lactamase 1 (NDM-1) was identified in 2009 by Yong et al. and 
constituted a novel subclass of B1 metalloenzymes.119 The blaNDM-1 gene was encoded on 
transmissible plasmids in two MDR K. pneumoniae and E. coli strains, isolated from urine 
and feces of the same patient, respectively. After hospitalization in New Delhi, India, the 
patient acquired a urinary tract infection, caused by the NDM-1 producing K. pneumonia, and 
was repatriated to Sweden.119 The NDM-1 enzyme shares little amino acid identity with other 
metallo-β-lactamases; VIM-1 and VIM-2 show the closest similarity, sharing 32.4% amino 
acid identity with NDM-1.119 Like other metallo-β-lactamases NDM-1 is active against almost 
all β-lactam agents, except aztreonam. However, transfer of NDM-1 into a susceptible E. coli 
strain has led to significant reduction in aztreonam susceptibility.119 NDM-1 is usually 
encoded on plasmids which often harbor other resistance genes. Commonly, NDM-1 
expressing isolates retain susceptibility only against tigecycline and colistin.120 Recent studies 
analyzed the epidemiology of blaNDM-1 in A. baumannii and Enterobacteriaceae, while little 
information was given on the genetic environment of the gene.120, 121 
 
In the following publication, we characterized the genetic composition of blaNDM-1 of a 
clinical A. baumannii isolate from Germany. The gene was located on a large composite 
transposon that inserted into a chromosomal major facilitator superfamily (MFS) symporter 
gene and was flanked by two copies of ISAba125, a common IS element in A. baumannii. In 
addition, parts of the transposon revealed genetic similarity to other Gram-negative species. 
For example, blaNDM-1-trpF was similar to K. pneumoniae plasmid pKpANDM-1 and the 
downstream located ΔgroS-groL-insE showed similarity to E. coli plasmids pEH4H and 
pAR060302. 
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2.2 Characteristics of the intrinsic OXA-51 subclass in A. baumannii 
 
2.2.1 Detection of intrinsic blaOXA-51-like by multiplex PCR on its own is not reliable for 
the identification of Acinetobacter baumannii 
 
The intrinsic OXA-51-like has so far been detected in every investigated A. baumannii 
isolate. Therefore, detection of a blaOXA-51-like-specific amplicon in the OXA-multiplex PCR 
described by Woodford et al., is often used for species identification.122 In the present 
publication we report unusual blaOXA-51-like amplicons detected by multiplex PCR in three 
clinical A. baumannii isolates, originating from different countries. Recently, Lopes et al. 
identified disruption of the intrinsic OXA gene by ISAba16 in a single A. baumannii 
isolate.123 Comparably, sequencing in our isolates revealed disruption of blaOXA-51-like by IS 
elements. In contrast to Lopes et al. we detected insertion of ISAba19 into blaOXA-78 in two 
epidemiologically related carbapenem-susceptible A. baumannii isolates, as well as insertion 
of ISAba15 into blaOXA-66 in a carbapenem-resistant isolate which also harbored an acquired 
OXA-23. Our results show that disruption of the intrinsic OXA-51-like gene in A. baumannii 
has occurred on more than one occasion and that the intrinsic gene is not necessary as an 
additional determinant for carbapenem resistance in the presence of acquired OXA. 
Furthermore our results indicate that detection of blaOXA-51-like by multiplex PCR may not be a 
fully reliable tool for A. baumannii species identification and should be confirmed by 
additional methods. 
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Due to copyright the full-length article is only part 
of the printed version of this dissertation. 
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2.2.2 Association between β-lactamase-encoding blaOXA-51 variants and DiversiLab rep-
PCR-based typing of Acinetobacter baumannii isolates 
 
Some A. baumannii clonal lineages are more prevalent than others, for example IC2. Various 
typing methods can be used to identify clonal lineages of A. baumannii, including sequence 
group typing, MLST and rep-PCR (see 1.1.5).73, 75, 76 The OXA-51-like gene is intrinsic to     
A. baumannii and shows great diversity, whereby blaOXA-51-like sequencing might be 
considered as a single locus typing method. Previous studies have investigated the correlation 
between blaOXA-51-like sequenced-based typing and MLST or sequence group typing.
76, 124 
However, these studies were limited to IC1 to IC3 and did not include other international 
clonal lineages. 
 
On the basis of a large collection of clinical A. baumannii isolates with worldwide origin we 
identified correlation between rep-PCR and eight previously described international 
(worldwide) clonal lineages,67 indicating that certain OXA-51-like genes belong to certain 
clonal lineages. Therefore blaOXA-51-like typing by sequencing might be a suitable indicator of 
IC1 to IC8. In contrast to a previous study we discovered that the nucleotide sequence is more 
convenient to analyze OXA-51-like relatedness, compared to the amino acid sequence.125 In 
addition, we identified five novel OXA-51 amino acid variants, OXA-200, OXA-201,       
OXA-202, OXA-219 and OXA-223, as well as a novel nucleotide variant, OXA-113a. 
Interestingly, the association of ISAba1 was restricted to certain OXA-51-like, for example 
OXA-82 and OXA-201, and was only detected in carbapenem-resistant isolates in the absence 
of acquired OXA. In contrast, more ancestral OXA variants like OXA-66 were not associated 
with ISAba1 and were detected either in carbapenem-susceptible isolates in the absence of 
other OXAs or in carbapenem-resistant isolates only when an acquired OXA was present. 
This might indicate influence of carbapenem selection on OXA-51-like evolution. 
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2.2.3 Conversion of OXA-66 into OXA-82 in clinical Acinetobacter baumannii isolates 
and association with altered carbapenem susceptibility 
 
In the present study three outbreak related A. baumannii isolates were investigated which 
were clonally related to each other but showed differences in their carbapenem susceptibility. 
The isolates were part of an outbreak in a hospital in Krakow as has been reported 
elsewhere.126 As no acquired OXAs were detected, the intrinsic OXA-51-like genes were 
further investigated. In A. baumannii the chromosomal blaOXA-51-like gene is located between 
the fxsA and yncA genes, which encode a suppressor for F exclusion of phage T7 and a 
phosphinothricin acetyltransferase, respectively. Based on these flanking genes primers were 
designed to confirm the chromosomal location of the OXA genes. Furthermore blaOXA-51-like 
and flanking regions were sequenced. This revealed presence of OXA-66 in the      
carbapenem-susceptible isolate, while the carbapenem-resistant isolates harbored ISAba1 and 
a point mutation in OXA-66, converting it into OXA-82. In correlation to our previous study          
(see 2.2.2), OXA-82 was associated with an upstream located ISAba1. As expected, OXA-82 
was overexpressed in both carbapenem-resistant isolates compared to OXA-66 in the 
carbapenem-susceptible isolate. Figueiredo et al. have recently detected a comparable 
ISAba1-mediated level of OXA-66 overexpression in a carbapenem-susceptible A. baumannii 
isolate.127 Therefore our results suggest that the single amino acid substitution contributes to 
carbapenem resistance in A. baumannii when the OXA gene is overexpressed. This was 
further investigated on the basis of an isogenic background and preliminary data are presented 
below (see: Unpublished results I). Transfer of blaOXA-82 with the ISAba1-mediated promoter 
into the A. baumannii reference strain ATCC 17978 conferred carbapenem resistance. In 
addition, no change in the outer membrane profile of the clinical isolates was observed. 
Therefore we considered the OXA conversion, coupled with ISAba1-mediated 
overexpression, as the sole carbapenem-resistance mechanism in both OXA-82-expressing     
A. baumannii isolates. 
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Unpublished results I 
 
To investigate the question whether it might be beneficial for A. baumannii to harbor one 
OXA-51 variant over another, the effect on carbapenem susceptibility of related blaOXA-51-like, 
overexpressed in the same strain, was analyzed. The initial idea was to perform a gene 
replacement of the chromosomal blaOXA-51-like in the carbapenem-susceptible A. baumannii 
reference strain ATCC 17978 using a double crossover reaction. As OXA-51-like genes 
usually harbor only a few point mutations, the replacement would be performed in two steps 
(Figure 10). 
 
blaOXA-51-like
yncA fxsAΔISAba1 blaOXA-51-likekanR
yncA
yncA
1st replacement
2nd replacement
fxsA
fxsA
tetA
PABA1
 
Figure 10: Two-step blaOXA-51-like replacement. Different colors of the blaOXA-51-like gene highlight that 
the parental gene (dark blue) will be replaced by other variants (grey). yncA, phosphinothricin 
acetyltransferase gene; fxsA, suppressor gene F exclusion of phage T7; ISAba1, partial insertion 
sequence A. baumannii 1, including the blaOXA-51-like promoter (PABA1); tetA; tetracycline resistance 
gene; kanR, kanamycin resistance gene; blaOXA-51-like, β-lactamase gene 
 
Together with parts of the blaOXA-51-like surrounding areas, including partial fxsA and yncA 
sequences, a tetracycline resistance gene (tetA) was cloned into the suicide vector pUC18. 
This vector does not contain an origin of replication for Acinetobacter and should therefore be 
unstable in the cell. Selective pressure should favor homologous recombination via double 
crossover and replace the chromosomal blaOXA-51-like with tetA. 
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This deletion mutant should have been used for a second round of gene replacement, where 
the tetA is replaced by different OXA-51-like variants together with the same promoter region 
provided by a partial ISAba1 to confer blaOXA overexpression. It is important not to clone the 
full IS element, i.e. a functioning transposase, to avoid its transposition. 
 
Although the first gene replacement was successful, we could not use the deletion mutant for 
further experiments, because unexpectedly the pUC18 construct persisted in the cell. All 
efforts to cure the plasmid from the ATCC 17978 blaOXA-51-like deletion mutant failed, 
including serial passages for two weeks under plasmid curing conditions, e.g. different 
concentrations of sodium-dodecyl sulfate (SDS) and incubation at 42°C. Therefore we 
decided to use the E. coli and A. baumannii shuttle vector pWH1266 as the backbone for 
cloning the constructs in cis. The use of a replicable plasmid was not the first choice for our 
investigation, as transformants might end up having multiple plasmid copies which would 
influence blaOXA-51-like expression levels. However, pWH1266 is considered to be a low copy 
plasmid, whereby the possibility of multiple plasmids in the cell should be negligible. Closely 
related blaOXA-51 variants, including blaOXA-66, blaOXA-82 and blaOXA-201 (see 2.2.2) were 
amplified from clinical A. baumannii isolates. All of these OXAs belong to the IC2 lineage 
and differ by only few amino acid substitutions. With regards to these substitutions, either 
OXA-82 or OXA-109 can be considered as an intermediate between OXA-66 and OXA-201 
(Figure 11). To include OXA-109 in our analyses, we generated the appropriate gene by     
site-directed mutagenesis. 
 
OXA-82
OXA-109
OXA-66 OXA-201
L167
V
L167
V
P130Q
P130Q
 
Figure 11: Representative OXA-51 variants of A. baumannii IC2 and amino acid substitutions 
responsible for OXA conversion. As indicated, OXA-201 might have evolved from either OXA-82 or 
OXA-109. L, leucine; P, proline; Q, glutamine; V, valine 
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The blaOXA genes were cloned together with partial blaOXA-51-like flanking regions from ATCC 
17978, approximately 300 bp of the ISAba1 element and a kanamycin resistance gene into a 
pWH1266 derivative, which lacked the ampicillin resistance gene. The cloned constructs were 
transferred into ATCC 17978 and blaOXA-51-like gene expression, as well as carbapenem 
susceptibility by Etest, was investigated. Although we observed overexpression of all cloned 
blaOXA-51 variants in the transformants, the effect on carbapenem susceptibility was different. 
Overexpression of OXA-66 slightly increased carbapenem MICs in ATCC 17978 (Table 5). 
In contrast, OXA-82, OXA-109 and OXA-201 conferred carbapenem resistance in the 
reference strain, suggesting an advantage of these enzymes over OXA-66 with regards to 
carbapenem susceptibility. However, the advantage of OXA-201 over OXA-82 or OXA-109 
remained unclear. 
 
Table 5: Carbapenem susceptibility of ATCC 17978 wildtype and blaOXA-51-like harboring 
transformants. 
Strain 
Carbapenem MIC [mg/L] 
Imipenem Meropenem 
ATCC 17978 0.25 0.25 
ATCC 17978-OXA-66 1 4 
ATCC 17978-OXA-82 >32 >32 
ATCC 17978-OXA-109 >32 >32 
ATCC 17978-OXA-201 8 (hR >32) 16 (hR >32) 
 
MIC, minimal inhibitory concentration; hR, MIC including heteroresistant colonies 
 
Interestingly, appearance of a heteroresistant phenotype was discovered in the OXA-201 
transformant, but so far it remains unclear if this phenotype provides any advantage for the 
transformant. Heteroresistance describes a phenomenon of diverse antimicrobial susceptibility 
to an agent within one isolate (Figure 12). This means the presence of a drug-resistant 
subpopulation among a more susceptible background population.128 For example, the 
inhibition zone next to an Etest stripe can harbor multiple colonies which grow up to higher 
drug concentrations (Figure 12). To avoid treatment failure, the MIC should be interpreted on 
the basis of the resistant population. The mechanism behind the heteroresistant phenotype has 
not been determined. 
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Figure 12: Carbapenem-heteroresistant A. baumannii. IP, imipenem; MP, meropenem 
 
I presented preliminary data of this work as part of an oral presentation at the 24th European 
Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain, 
in May 2014.129 
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2.3 Insertion sequence mediated overexpression of intrinsic carbapenem-
hydrolysing OXA in non-baumannii Acinetobacter species 
 
2.3.1 Identification of a novel insertion sequence element associated with carbapenem 
resistance and the development of fluoroquinolone resistance in Acinetobacter 
radioresistens 
 
OXA-23 (formerly ARI-1) was first identified in 1995 and was detected in an imipenem-
resistant A. baumannii isolate from Scotland.8 To date, OXA-23-like is the most commonly 
detected acquired OXA subclass in A. baumannii, but it has also been detected in                
non-baumannii Acinetobacter species.54, 130 The origin of this subclass remained unknown 
until in 2008 OXA-23 was identified in carbapenem-susceptible A. radioresistens isolates.112 
To date, six amino acid variants have been identified in this species; OXA-23, OXA-102, 
OXA-103, OXA-105, OXA-133 and OXA-134 (see 3.2).112, 131 Acquired blaOXA-23-like are 
usually associated with carbapenem resistance due to IS-mediated overexpression. In contrast, 
the intrinsic OXA-23 variants in A. radioresistens do not confer carbapenem-resistance and 
have so far not been detected in association with IS elements. 
 
The following publication reports the first detection of an IS element upstream of blaOXA-23 in 
two carbapenem-resistant A. radioresistens isolates, recovered before and after institution of 
ciprofloxacin therapy from the same patient. In addition, a shift in ciprofloxacin susceptibility 
was discovered between the two isolates which was associated with a gyrA mutation. A novel 
insertion sequence ISAcra1 was identified, which conferred overexpression of the intrinsic 
OXA in the clinical isolates compared to the carbapenem-susceptible A. radioresistens 
reference strain SH164. Cloning and transfer of blaOXA-23 together with a partial ISAcra1 
conferred carbapenem resistance in A. baumannii and A. radioresistens reference strains. 
Association of the intrinsic OXA-23 in A. radioresistens with an IS element indicates 
potential spread of carbapenem resistance in this species and dissemination of ISAcra1-
blaOXA-23 in the genus Acinetobacter. 
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2.3.2 Insertion sequence IS18 mediates overexpression of blaOXA-257 in a carbapenem-
resistant Acinetobacter bereziniae isolate 
 
A. bereziniae harbors the intrinsic OXA-228-like, which is usually expressed at low level and 
thus does not confer carbapenem resistance. However, overexpression of blaOXA-228-like has 
recently been detected in a clinical A. bereziniae isolate from France, which was associated 
with reduced carbapenem susceptibility.132 Increased blaOXA expression was due to alterations 
in the predicted promoter sequences, while no adjacent IS element was detected. 
 
In the following publication the first case of IS-mediated blaOXA-228-like overexpression in        
A. bereziniae is reported. The insertion sequence IS18 was detected adjacent to a novel    
OXA-228 variant, OXA-257, in a carbapenem-resistant A. bereziniae isolate from Germany. 
Sequence analysis of the blaOXA-257 upstream region revealed the presence of two putative 
promoters, partially provided by IS18. Cloning and transfer of blaOXA-257 and the putative 
promoters conferred carbapenem resistance in A. baumannii ATCC 17978. This highlights the 
potential of the OXA-228 subclass to confer carbapenem-resistance outside of A. bereziniae. 
Furthermore association with an IS element, usually associated with A. baumannii, indicates 
possible mobilization of the gene which would support its dissemination in the genus 
Acinetobacter. 
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Figure S1. Orientation of IS18 and predicted promoter sequences upstream of blaOXA-257. 
Inside the right inverted repeat (IRR, coloured yellow) are two –35 boxes. Blue shading 
shows a predicted –35 box and –10 box (the –35 box is also described in IS18). Red shading 
shows a hybrid promoter based on those described in Acinetobacter bereziniae Nec and Baz. 
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Inside the right inverted repeat (IRR, coloured yellow) are two –35 boxes. Blue shading shows a 
predicted –35 box and –10 box (the –35 box is also described in IS18). Red shading shows a hybrid 
promoter based on those described in Acinetobacter bereziniae Nec and Baz. 
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2.4 Distribution and novel insights into acquired carbapenem-hydrolysing 
OXA in Acinetobacter spp. 
 
2.4.1 Worldwide dissemination of acquired carbapenem-hydrolysing class D  
β-lactamases in Acinetobacter spp. other than Acinetobacter baumannii 
 
In the literature, there are reports of carbapenem-hydrolysing class D β-lactamases in          
non-baumannii Acinetobacter spp. These include various subclasses of metallo-β-lactamases 
and oxacillinases.133-137 Similar to A. baumannii, carbapenem resistance is more often 
associated with acquired oxacillinases than metallo-β-lactamases. 
 
In the following publication the dissemination of acquired OXA in 453 non-baumannii 
Acinetobacter spp. isolates of worldwide origin was investigated. Oxacillinases were detected 
in 23 isolates by OXA-multiplex PCR, with a high rate (47.8%) of false-positive blaOXA 
detection. This indicates that the multiplex PCR is not a reliable tool for identification of 
blaOXA subclasses in non-baumannii Acinetobacter spp. blaOXA were mainly present in 
carbapenem-resistant Acinetobacter isolates, adjacent to ISAba1 (blaOXA-23) and ISAba3 
(blaOXA-58). Partial sequencing of ISAba3 upstream of blaOXA-58 revealed no difference 
between carbapenem-resistant and carbapenem-susceptible isolates, suggesting the presence 
of additional strain-dependant carbapenem-resistance determinants. For the first time OXA-23 
in Acinetobacter genomic species 14TU/13BJ, OXA-255 (a novel OXA-143 variant; see 
2.4.3) in A. pittii and OXA-23 together with OXA-58 in A. pittii were detected. In addition, 
acquired OXA were for the first time detected in Acinetobacter spp. from South Africa and 
North America. 
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Due to copyright the full-length article is only part 
of the printed version of this dissertation. 
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2.4.2 OXA-235, a novel class D β-lactamase involved in resistance to carbapenems in  
Acinetobacter baumannii 
 
A novel subclass of acquired CHDL in A. baumannii was identified and characterized. 
Detection of OXA-235-like in carbapenem-resistant A. baumannii isolates highlights the 
potential of this species to acquire novel resistance determinants. The novel subclass was 
identified in ten carbapenem-resistant A. baumannii isolates that originated from the USA and 
Mexico. The majority of isolates harbored OXA-235, while two single isolate harbored the 
amino acid variants OXA-236 and OXA-237, respectively. The subclass shows the highest 
amino acid identity with OXA-134a (85%), a member of the intrinsic subclass of 
Acinetobacter lwoffii,138 which should not be confused with OXA-134 from A. radioresistens 
(see 2.3.1 and 3.2). OXA-235-like genes were flanked by two ISAba1 and were mainly 
encoded on plasmids. In Acinetobacter baylyi, a well-established model organism of the 
genus, and A. baumannii ATCC 17978, OXA-235 mediated reduced carbapenem 
susceptibility but not carbapenem resistance. However, some of the clinical isolates harbored 
multiple blaOXA-235-like copies which probably affected the overall blaOXA expression and may 
partly explain MIC differences between the parent strains and the transformants. The ability 
of OXA-235 to alter carbapenem susceptibility and its association with ISAba1 suggests 
further spread in the genus Acinetobacter. To facilitate monitoring of worldwide              
OXA-235-like prevalence, inclusion of blaOXA-235-like primers in the OXA-multiplex PCR was 
established. 
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Supplementary data 
 
 
Supplemental figure S1. Dendrogram and Ziggurat figure showing rep-PCR fingerprints of            
OXA-235-like positive A. baumannii. 
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2.4.3 Characterization of blaOXA-143 variants in Acinetobacter baumannii and 
Acinetobacter pittii 
 
To date, the acquired OXA-143 subclass has mainly been detected in carbapenem-resistant     
A. baumannii from Brazil and compromises two designated amino acid variants (OXA-143 
and OXA-231).110, 139-141 However, little information is given on the genetic environment of 
blaOXA-143-like. 
 
The following publication reports blaOXA-143-like detection in two carbapenem-resistant             
A. baumannii isolates from Brazil and Honduras, as well as a carbapenem-susceptible A. pittii 
isolate from the USA. Sequencing identified the OXA-143 variants OXA-231 and OXA-253 
in the A. baumannii isolates, as well as OXA-255 in the A. pittii isolate. Furthermore, a 
similar genetic context was discovered for blaOXA-231 compared to the published sequence of 
blaOXA-143, while the genetic environment of the other two variants differed. For the first time 
the blaOXA-143-like transcription initiation site was determined, which led to the identification of 
putative promoter sequences. Regardless of differences in the predicted promoter sequences, 
all OXA-143 variants conferred carbapenem-resistance in the A. baumannii reference strain 
ATCC 17978. In contrast to the clinical isolate, OXA-255 also conferred                 
carbapenem-resistance in the A. pittii reference strain SH024, which was associated with 
blaOXA-255 expression. Identification of OXA-255 in A. pittii highlights the potential of this 
subclass to spread in non-baumannii Acinetobacter species. Interestingly, Girlich et al. 
recently reported presence of OXA-253 in A. baumannii from Brazil, which indicates 
distribution of this OXA-143 variant in the Western Hemisphere.142 
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Supplementary data continued 
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Unpublished results II 
 
Previous studies have reported an effect of certain physiological conditions on antimicrobial 
susceptibility in Gram-negative bacteria. For example, 8 mM sodium-salicylate and pH 6.0 
have been reported to affect fluoroquinolone susceptibility and induce expression of the porin 
OmpC in Serratia marcescens.143, 144 In addition, 4-32 mM sodium-salicylate has been 
reported to decrease porin expression in P. aeruginosa, which can be associated with 
carbapenem resistance.145, 146 Interestingly, an effect of physiological conditions on 
antimicrobial susceptibility has also been reported in A. baumannii. For example, it has been 
shown that pH 5.8 alters fluoroquinolone susceptibility in clinical A. baumannii isolates.147 
Other studies reported altered porin expression in the presence of 16 mM sodium-salicylate or 
200 mM NaCl, which can be associated with carbapenem resistance.116, 148 For example, 
Hood et al. have reported that gene expression of the porins CarO and the 33-36 kDa Omp in 
ATCC 17978 is reduced in the presence of NaCl.148 However, when we analyzed the outer 
membrane protein profiles of ATCC 17978 grown in Mueller-Hinton broth under different 
physiological conditions (200 mM NaCl, 16 mM sodium-salicylate, pH 5.8) we could not 
detect significant changes compared to standard conditions (pH 7.2) (data not shown). 
Interestingly, it is also reported that the majority of OXA in A. baumannii are inhibited in 
vitro in the presence of NaCl.110, 149-151 However, kinetic data on OXA-23 are missing and 
data on OXA-40 are contradictory. For example, one study reported complete inhibition of 
OXA-40 by 1 mM NaCl, while a different study reported half maximal inhibition in the 
presence of 3 M NaCl.150, 152 However, the inhibitory effect of NaCl on purified OXA 
enzymes has led some researchers to screen for the presence of OXA by performing 
carbapenem MICs in media supplemented with 200 mM NaCl.94, 153, 154 A 4-fold reduction of 
the carbapenem MIC in the presence of NaCl was considered to be significant for OXA 
inhibition. The susceptibility of each transformant was compared to the respective recipient. 
The cloned OXA genes were blaOXA-219 (blaOXA-51 variant; see 2.2.2), blaOXA-23, blaOXA-40, 
blaOXA-143, blaOXA-58 and blaOXA-164 (blaOXA-58 variant)
155. Carbapenem susceptibility testing 
was performed under standard testing conditions (Mueller-Hinton agar, pH 7.2; incubation at 
37°C), as well as Mueller-Hinton agar supplemented with 16 mM sodium-salicylate, 200 mM 
NaCl and pH 5.8. The results are summarized in Table 6. 
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Table 6: The effect of different physiological conditions on carbapenem susceptibility in A. baumannii 
ATCC 17978 and ATCC 19606 and their transformants harboring pWH1266::blaOXA recombinant 
plasmids. Significant MIC reductions (≥ 4-fold) under certain conditions are highlighted in bold and 
red color. 
OXA (ATCC strain) 
Imipenem MIC [mg/L] Meropenem MIC [mg/L] 
MHA pH 5.8 NaCl 
sodium-
salicylate 
MHA pH 5.8 NaCl 
sodium-
salicylate 
17978 0.25 0.5 0.25 0.25 1 2 0.5 1 
19606 0.25 0.5 0.25 0.5 1 1 1 1 
219 (51-like) (17978) 32 8 16 8 128 32 64 64 
219 (51-like) (19606) 16 8 8 8 64 32 64 64 
40 (17978) 128 64 64 64 512 128 128 128 
40 (19606) 64 32 32 64 256 64 64 128 
23 (17978) 32 32 32 32 256 32 64 32 
23 (19606) 64 32 64 32 256 128 64 128 
143 (17978) 128 64 64 32 >512 256 256 256 
143 (19606) 64 64 32 64 512 256 256 128 
58 (17978) 32 8 16 32 64 8 8 32 
58 (19606) 64 8 32 16 64 8 32 32 
164 (58-like) (17978) 32 8 16 16 32 8 8 16 
164 (58-like) (19606) 32 8 16 16 32 8 8 8 
 
MIC, minimal inhibitory concentration; MHA, Mueller-Hinton agar 
 
Carbapenem susceptibility of the reference strains was not affected under the different 
physiological conditions (Table 6). Interestingly, the effect of the tested conditions on 
carbapenem susceptibility of OXA-23, OXA-40, OXA-143 and OXA-219 was dependent on 
the strain. For example, MICs of OXA-219 in ATCC 17978 were reduced under low pH 
(imipenem and meropenem) and sodium-salicylate (imipenem), whereas MICs in ATCC 
19606 were unaffected. 
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Both OXA-40 transformants showed reduced meropenem susceptibility under low pH and 
presence of NaCl, while no change for imipenem was detected. Interestingly, all OXA-58-like 
transformants revealed a reduction of the carbapenem MICs under pH 5.8 (Table 6). 
 
I presented preliminary data of this work as part of an oral presentation at the 21th European 
Congress of Clinical Microbiology and Infectious Diseases (ECCMID)/27th International 
Congress of Chemotherapy (ICC) in Milan, Italy, in 2011.156 Data of Table 6 were part of a 
poster at the 9th International Symposium on the Biology of Acinetobacter in Cologne, 
Germany, in 2013.157 
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3. Concluding discussion 
 
Currently, carbapenems are considered as the antibiotics of choice to treat infections with 
MDR Gram-negative bacteria, including A. baumannii. Alarmingly, carbapenem-resistance 
rates in A. baumannii are rising and carbapenem-resistance determinants in non-baumannii 
Acinetobacter species are increasingly reported, which highlights the need for novel treatment 
strategies.99, 135, 136, 158 The dissemination of carbapenem-hydrolysing β-lactamase genes is 
supported by their genetic alterability which is based on mutations and association with 
mobile genetic structures, like plasmids, transposons and IS elements. 
 
The work presented in this thesis highlights the diversity of carbapenem-hydrolysing enzymes 
in the genus Acinetobacter and gives novel insights into their genetic context and 
dissemination. Table 7 and Table 8 summarize novel OXA variants and genetic compositions 
associated with carbapenem resistance in Acinetobacter spp., which were identified over a 
three-year period. 
 
Table 7: Novel OXA variants identified in Acinetobacter spp. 
*If not mentioned otherwise the variation is based on the amino acid sequence. 
 
OXA subclass Variant* Species Reference 
OXA-51-like 
OXA-113a (nucleotide variant of OXA-113), 
OXA-200, OXA-201, OXA-202,       
OXA-219, OXA-223, OXA-241,      
OXA-242, OXA-387, OXA-391 
A. baumannii 
Higgins et al.111, 159   
accession no. OXA-387: 
KJ173478          
accession no. OXA-391: 
KJ427797 
OXA-23-like OXA-225 A. baumannii accession no.: JN638887 
OXA-143-like OXA-231, OXA-253, OXA-255 
A. baumannii and 
A. pittii 
Zander et al.160 
OXA-235-like OXA-235, OXA-236, OXA-237 A. baumannii Higgins et al.111 
OXA-228-like OXA-257 A. bereziniae Zander et al.161 
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Table 8: Novel insights into the genetic composition of carbapenemase genes in Acinetobacter spp. 
bla, β-lactamase gene; IS, insertion sequence 
 
These results underline the rapid evolution of carbapenem-resistance genes and their potential 
for transmission in the genus Acinetobacter. 
 
3.1 ISAba125-associated blaNDM-1 in Acinetobacter spp. 
 
Due to their potential to act against the whole class of β-lactams (with exception of 
monobactams), metallo-β-lactamases are of great concern in the clinic. Compared to CHDL, 
metallo-β-lactamases are rarely reported in Acinetobacter spp. Since the identification of 
NDM-1 in 2009, eight amino acid variants have been identified (NDM-1 to NDM-8), which 
mainly emerged in E. coli, K. pneumoniae and P. aeruginosa isolates with a wide distribution 
in India. However, NDM-1 and NDM-2 have also been detected in MDR A. baumannii from 
different parts of the world, including Algeria, China, Egypt, Germany, India, Israel and 
Oman.164 Recently, NDM-1-producing MDR A. pittii, A. johnsonnii and A. lwoffii from China 
were reported, highlighting distribution of the subclass within the genus Acinetobacter.165-167 
 
bla gene Genetic context Species Reference 
blaNDM-1 
composite transposon bracketed by 
ISAba125; chromosomal location 
A. baumannii Pfeifer et al.162 
blaOXA-23 upstream inserted ISAcra1 A. radioresistens Higgins et al.163 
blaOXA-143-like 
blaOXA-231: downstream located 
replicase gene 
blaOXA-253: bracketed by XerC/D 
recombination sites;  upstream located 
inner membrane protein gene 
blaOXA-255: bracketed by TonB-
dependent receptor gene and peptidase 
gene 
A. baumannii and A. pittii Zander et al.160 
blaOXA-257 upstream inserted IS18 A. bereziniae Zander et al.161 
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The NDM-1-producing A. baumannii 161/07 from Germany (see 2.1) was isolated in 2007 
prior to the isolation of the K. pneumonia and E. coli strains the gene was first identified  
in.119, 162 Although India is proposed to be the origin of NDM-1, A. baumannii 161/07 was 
isolated from a patient repatriated from Serbia without a connection to India, which also 
suggests the Balkan as a potential origin of NDM-1. In A. baumannii 161/07 blaNDM-1 was 
encoded on a composite transposon, which was flanked by two copies of ISAba125 and had 
inserted into a chromosomal MFS symporter. The trpF and groS-groL-insE regions have been 
frequently detected in the genetic environment of blaNDM-1 in different genera, suggesting the 
same genetic origin of these regions.168 Recently Poirel et al. identified the same transposon 
in two A. baumannii isolates and assigned it as Tn125, which is proposed to be the major 
driving force for NDM distribution in A. baumannii.169 In contrast to A. baumannii 167/07, 
the transposon had inserted into chromosomal genes of unknown function, which highlights 
the presence of multiple insertion sites for Tn125 on the A. baumannii genome. Furthermore, 
almost identical transposons have been recently identified on plasmids in                  
carbapenem-resistant A. lwoffii,168 which suggests mobilization from the A. baumannii 
genome. The transposons in A. lwoffii were located next to an aminoglycoside resistance gene 
(aphA6). The same gene was also detected in A. baumannii 161/07, where it was flanked by 
ISAba125. Interestingly, aphA6 seems to be involved in the genesis of blaNDM-1.          
Toleman et al. have recently shown that blaNDM-1 is a chimeric gene composed of the first      
19 bp of aphA6 and a preexisting metallo-β-lactamase gene.170 It was proposed that the          
in-frame fusion of both genes resulted in beneficial changes in gene expression and the 
structure of the enzyme.170 
To date, NDM and other metallo-β-lactamase subclasses are still rarely detected in                 
A. baumannii and might not emerge as a global threat for human health. However, the 
dissemination of NDM variants in MDR Acinetobacter spp. should be regarded with concern. 
As with other carbapenem-resistant A. baumannii isolates NDM-expressing isolates often 
retain only susceptibility to colistin or tigecycline, which highlights the need for new 
treatment strategies. Like CHDLs, metalloenzymes are stable against β-lactamase inhibitors, 
whereby a combination with β-lactam agents would be ineffective against NDM-producing 
bacteria. Currently, available agents that target metallo-β-lactamases are missing. However, 
putative inhibitors such as sulfur-containing compounds and dicarboxylates with zinc-binding 
properties have been recently reported, which highlights the potential for the development of 
novel treatment options.171 
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3.2 The diversity of OXA carbapenemases in Acinetobacter spp. 
 
The genus Acinetobacter harbors a wide spectrum of carbapenem-hydrolysing OXA enzymes. 
This includes acquired and intrinsic OXA subclasses. Between 2008 and 2014 multiple 
intrinsic OXA subclasses have been identified in Acinetobacter species other than                 
A. baumannii, which are summarized in Table 9.93, 112, 105, 132, 138, 172 
 
Table 9: Intrinsic OXA subclasses and the respective number of variants identified in non-baumannii 
Acinetobacter species. 
Intrinsic OXA 
subclass 
Acinetobacter species 
Number of amino 
acid variants 
23 A. radioresistens 6 
134a# A. lwoffii and A. schindleri 10 
211 A. johnsonii 7 
214 A. haemolyticus 5 
213 A. calcoaceticus, A. pittii and AGS `between 1 and 3´ 27 
228 A. bereziniae and A. guillouiae 10 
266 A. venetianus 1 
279 A. parvus and AGS 6 3 
286 
AGS 14TU/13BJ, AGS 16, AGS 17, 
Taxon 19*, Taxon 21* and Taxon 22* 
10 
294 AGS 14BJ and Taxon 20* 4 
296 Taxon 96* 1 
299 A. bouvetii 1 
308 A. gerneri 1 
 
#OXA-134a is not identical to the OXA-23 variant OXA-134 in A. radioresistens; *putative novel species105; 
AGS, Acinetobacter genomic species 
 
The intrinsic OXA-134a subclass from A. lwoffii (accession no.: HQ122933) is not related to 
the OXA-23 variant OXA-134 in A. radioresistens (accession no.: FJ195387) (see 2.3.1). The 
terms OXA-134 and OXA-134a, which are used in this thesis, correspond to the respective 
GenBank submissions. However, it should be noted that the number 134 was assigned on the 
basis of the A. lwoffii sequence (http://www.lahey.org/Studies/). 
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The diversity of naturally occurring OXA subclasses in Acinetobacter spp. may indicate a 
broad range of silent carbapenem-resistance determinants in the Acinetobacter genus, which 
remains to be confirmed. However, in A. baumannii IS-mediated overexpression of the 
intrinsic blaOXA-51-like is the most common carbapenem-resistance mechanism in the absence of 
acquired OXA. In addition, we have identified a similar carbapenem-resistance mechanism in 
A. radioresistance and A. bereziniae.161, 163 This shows that carbapenem resistance due to      
IS-mediated overexpression of intrinsic blaOXA is not limited to A. baumannii. Moreover, the 
ability of IS elements to change their genetic location in addition to the variety of IS elements 
which have already been identified in Acinetobacter spp., indicates an almost unlimited 
potential for blaOXA overexpression. The insertion sites of a certain IS element upstream of a 
specific gene seem to be located at the same position. For example, ISAba1 usually inserts      
9 bp upstream of the ampC start codon in A. baumannii.173 Furthermore, sequences available 
at GenBank reveal that adjacent to blaOXA-51-like ISAba1 is usually located 7 bp upstream of 
the start codon.  In A. radioresistens ISAcra1 inserted into ATATAA, which was located      
62 bp upstream of blaOXA-23 (see 2.3.1).
163 In contrast A. bereziniae IS18 inserted into TTT, 
which was located 37 bp upstream of the blaOXA-257 start codon (see 2.3.2). To analyze the 
presence of the respective insertion sites adjacent to blaOXA-23-like in A. radioresistens and 
blaOXA-228-like in A. bereziniae, available sequences from each species at GenBank were 
aligned. This revealed the presence of the same insertion site for ISAcra1 adjacent to     
blaOXA-23-like in A. radioresistens and for IS18 adjacent to blaOXA-228-like in A. bereziniae, 
respectively. The location of the ISAcra1 insertion site varied between 62 and 64 bp upstream 
of the OXA gene. It remains unknown, if these differences in the location of the insertion site 
significantly alter the promoter and thereby the effect on blaOXA-23-like expression. 
 
As chromosomally encoded OXA subclasses are often species-specific, PCR amplification 
using subclass-specific primers is thought to be reliable for species identification. For 
example, the OXA-multiplex PCR described by Woodford et al. can aid in the identification 
of A. baumannii.122 Furthermore, detection of OXA-134a-like has been proposed for A. lwoffii 
and A. schindleri identification.174 However, presence of these intrinsic OXA in other 
Acinetobacter species indicates blaOXA mobilization, which seems to be associated with IS 
elements. For example, in A. radioresistens blaOXA-23-like is adjacent to an ATPase gene. 
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This gene is also commonly adjacent to acquired blaOXA-23-like (e.g. in Tn2006), whereby a 
former mobilization together with the intrinsic gene from A. radioresistens seems likely.112 In 
addition to A. radioresistens, the intrinsic blaOXA-51-like from A. baumannii has been mobilized. 
Recently, Chen et al. detected presence of two ISAba1-blaOXA-51-like copies in A. baumannii, 
one located on the chromosome and one located on a plasmid.175 Similar to the A. baumannii 
chromosome, yncA was located adjacent to blaOXA-51-like on the plasmids. In addition,            
Lee et al. reported the emergence of plasmid-associated ISAba1-blaOXA-51-like-yncA in 
carbapenem-resistant A. nosocomialis and Acinetobacter genomic species `close  to 13TU´, 
indicating dissemination of OXA-51-like in non-baumannii Acinetobacter species. The 
mobilization of intrinsic OXA from A. radioresistens and A. baumannii highlights the 
potential of other intrinsic OXA genes to be mobilized and disseminate outside of their parent 
species. Interestingly, the insertion sequence IS18, which mediated overexpression of     
blaOXA-257 in A. bereziniae KH243, has already been detected in other Acinetobacter species. 
For example, in A. baumannii and A. nosocomialis IS18 has been associated with blaOXA-58-like 
and the aminoglycoside-resistance gene aac(6’)-Ij, respectively.176, 177 Presence of IS18 in 
these species highlights the existence of potential insertion sites for IS18 transposition, 
whereby emergence of IS18-blaOXA-257 in A. nosocomialis and A. baumannii in the 
foreseeable future seems likely. Based on these data, potential mobilization of intrinsic   
blaOXA in the genus Acinetobacter strongly suggests that detection of these genes should not 
be considered as an unambiguous method for species identification.178 
 
In addition to OXA-23-like and OXA-51-like, four acquired subclasses of carbapenem-
hydrolysing oxacillinases have been identified in Acinetobacter spp.; OXA-40-like,           
OXA-58-like, OXA-143-like and the novel OXA-235-like (see 2.4.2).111 In contrast to    
OXA-51-like and OXA-23-like, the origin of other acquired OXA subclasses remains 
unknown. Acquired OXA are globally detected in carbapenem-resistant A. baumannii, with 
OXA-23-like being the most prevalent67, and are increasingly reported in non-baumannii 
Acinetobacter spp. For example, subclasses OXA-23 and OXA-58 are widespread in 
carbapenem-resistant non-baumannii Acinetobacter spp. originating mainly from Asia and 
Europe, with a high distribution in A. pittii and A. nosocomialis.130, 158, 179-181 
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The recent detection of OXA-23 in A. nosocomialis from South Africa, as well as OXA-58 in 
A. junii from Australia indicate worldwide distribution of both subclasses in Acinetobacter 
species.158, 182 To date, OXA-235-like has only been detected in A. baumannii from Mexico 
and the USA, which is based on the ten isolates the subclass was first identified in.111 
 
Compared to OXA-23-like and OXA-58-like, subclasses OXA-40 and OXA-143 are less 
frequently reported in Acinetobacter spp. Regarding worldwide dissemination, OXA-40 
variants are prevalent in carbapenem-resistant Acinetobacter spp. from Europe, Asia and 
South America, with a wide distribution in A. baumannii and A. pittii.133, 183, 184 Interestingly, 
OXA-72 seems to be the most prevalent OXA-40 variant detected in both species.133, 158, 184 
Recent reports also indicate the emergence of the OXA-40 subclass in A. baylyi,                      
A. calcoaceticus, A. haemolyticus and A. junii.185-187 In contrast to the other acquired OXA 
subclasses in Acinetobacter spp., the presence of IS elements upstream of blaOXA-40-like and 
blaOXA-143-like is unusual. For example, since its first description in 2000, association of blaOXA-
40-like with an IS element has only been detected once, while so far no IS element has been 
detected upstream of blaOXA-143-like.
150, 160, 183 As explained before, IS elements can be involved 
in the mobilization of blaOXA, which may explain why OXA-40 and OXA-143 subclasses are 
less frequent. Furthermore, IS elements can provide full-length or partial promoters (see 1.4). 
Partial promoter regions (e.g. a -35 region) can generate a hybrid promoter with the natural 
blaOXA promoter (e.g. a -10 region). As IS elements commonly confer blaOXA overexpression 
it seems obvious that promoters provided by IS elements are stronger than the natural blaOXA 
promoters. Interestingly, alignment of the three blaOXA-143-like predicted promoter regions with 
blaOXA-40-like sequences in A. baumannii and A. haemolyticus revealed high similarity     
(Figure 13). The associated blaOXA-40-like sequences shown in Figure 13 are based on six 
sequences which were available at GenBank. Compared to OXA-143-like, a nucleotide 
substitution was identified at position 28 upstream of the blaOXA-40-like start codons. 
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+ 1- 10 blaOXA start codon- 35
Results
OXA-231   TTTCAATAATTGAATTAAAATATTATACTTTAGGCACTCAAAACTTTCCCTAACATAAATCTGTAATG
OXA-253   TTTAGGTTTTTGAATTAAAATATTATACTCTAGGCACTCAAAATTTCCCCTAACATAAATCTGTAATG
OXA-255   TTTAACTTTTTGAATTAAAATATTATGCTCTAGGCACTCAAAACTTCCACTAACGTAAATCTGTAATG
OXA-40 (A) TTTAACTTTTTTAATAAAAATATTATACTCTAAGCCC-CAAAATTTCCCCTAACATGAATTTGTAATG 
OXA-40 (B) TTTAACTTTTTTAATAAAAATATTATGCTCTAAGCCC-CAAAATTTCCCCTAACATGAATTTGTAATG
 
Figure 13: Alignment of predicted blaOXA-143-like promoter regions with sequences upstream of      
blaOXA-40-like. The blaOXA start codon, blaOXA-143-like transcription initiation sites and predicted -35 and     
-10 regions are highlighted with boxes. (A) Sequence upstream of blaOXA-40 in A. baumannii and         
A. haemolyticus; (B) Sequence upstream of blaOXA-40 in A. baumannii (identical to sequences adjacent 
to blaOXA-72 and blaOXA-160); –, nucleotide deletion compared to sequences upstream of blaOXA-143-like. 
 
The promoter sequences that were predicted for blaOXA-143-like were also present upstream the 
OXA-40-like genes. The predicted -35 region from blaOXA-255 was detected in all sequences 
(Figure 13). Furthermore, the predicted -10 region from blaOXA-231 and blaOXA-253 was present 
upstream of blaOXA-40 in A. baumannii and A. haemolyticus (accession no.: AY228470, 
JN982951 and JN982952), while the predicted -10 region from blaOXA-255 was present 
upstream of blaOXA-40, blaOXA-72 and blaOXA-160 in three A. baumannii sequences (accession 
no.: GU199038, GU199039 and GU199040). In contrast to OXA-40-like and OXA-143-like, 
comparison of other blaOXA upstream regions in A. baumannii did not reveal such a similarity 
between two different subclasses. To date, transcription initiation sites of blaOXA-40-like have 
not been identified. However, as OXA-40-like and OXA-143-like are usually not associated 
with IS elements, the similarity between their upstream regions suggests the presence of 
stronger natural promoters compared to other acquired OXA subclasses in Acinetobacter spp. 
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3.3 The alterability of carbapenem susceptibility in A. baumannii 
 
Previous studies have shown that physiological conditions, like low pH and presence of NaCl 
or sodium-salicylate can affect carbapenem-resistance determinants in A. baumannii.116, 143, 
147, 148 Based on these results one might speculate that because the physiological conditions at 
the site of an infection in the human body are variable, this might impact upon antimicrobial 
susceptibility. For example, in contrast to standard susceptibility testing methods, the pH in 
infected body fluids and tissues is often lower than pH 7.2.147 However, our results indicate 
that the effect of the tested physiological conditions on carbapenem susceptibility in               
A. baumannii is mainly strain-dependent (see 2.4, Unpublished results II). With the exception 
of OXA-58-like transformants there was no consistent reduction of carbapenem MICs under 
pH 5.8, 200 mM NaCl or 16 mM sodium-salicylate. MICs were not reduced to the wildtype 
level, which suggests that the transformants retained some OXA activity. It should be noted 
that although some OXA enzymes are inhibited by NaCl, this does not seem to influence 
carbapenem susceptibility in vivo, which could be due to strain-dependent regulatory 
mechanisms. Therefore carbapenem MICs in the presence of NaCl is not a reliable method to 
detect OXAs. Interestingly, pH 5.8 reduced carbapenem susceptibility in all OXA-58-like 
transformants from a resistant level to a non-susceptible level. This might indicate a potential 
selective advantage for A. baumannii in expressing OXA-58 and OXA-164 under pH 5.8 in 
the presence of carbapenems, however this remains to be determined. 
 
It has already been shown that carbapenem resistance can rapidly develop within the same 
strain. For example, we investigated a conversion of OXA-66 into OXA-82 in outbreak-
related A. baumannii isolates, which was associated with the presence of ISAba1 and 
carbapenem resistance (see 2.2.3).188 Interestingly, the intrinsic OXA-51-like from                  
A. baumannii exhibits the largest number of amino acid variants within a single subclass. 
Since the first identification of OXA-51 in 2005, currently 106 variants have been identified 
(http://www.lahey.org/Studies/).99, 189 The correlation between OXA-51 variants and 
international clonal lineages in A. baumannii indicates the evolution of an ancestral          
OXA-51-like within these lineages (see 2.2.2). 
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As mutations can randomly occur during DNA-replication, single A. baumannii cells within a 
population might not always harbor the same OXA-51-like. Regarding the diversity of    
OXA-51 variants within a single IC lineage, it could be proposed that some OXA-51 variants 
may be more beneficial for the bacterium than others. For example, in the absence of acquired 
OXA, carbapenem resistance seems to be associated with certain OXA-51 variants and the 
presence of ISAba1. This might indicate that more ancestral OXA-51-like are not as efficient 
in carbapenem hydrolysis as their closely related variants, which remains to be confirmed by 
enzyme kinetics. Using an isogenic background we have shown that overexpression of     
OXA-82, OXA-109 or OXA-201 confers carbapenem resistance in A. baumannii ATCC 
17978, while the OXA-66-expressing transformant remained susceptible (see 2.2, 
Unpublished results I). But if overexpressed OXA-82 and OXA-109 already confer 
carbapenem-resistance, the question comes up, what might be the advantage of a conversion 
into OXA-201? We have already shown that pH 5.8 can reduce carbapenem susceptibility in 
A. baumannii from a resistant to a non-susceptible phenotype. Therefore it might be possible 
that, compared to the OXA-201-expressing transformant, carbapenem susceptibility of    
OXA-82- or OXA-109-expressing transformants could be reduced under a physiological 
condition that we have not yet tested. Preliminary carbapenem susceptibility testing in the 
presence of 200 mM NaCl, 16 mM sodium-salicylate, pH 5.8 and incubation in the presence 
of CO2 did not reveal significant differences between the OXA transformants with regards to 
their MICs versus carbapenems (data not shown). However, as carbapenems are not the sole 
substrates for CHDL it is also possible that the OXA-201-expressing transformant shows 
higher MICs in the presence of other β-lactam agents, which remains to be elucidated. 
Summary 
 
101 
4. Summary 
 
Acinetobacter baumannii is a hospital-acquired pathogen which causes global concern in 
health-care facilities, because this Gram-negative bacterium can easily thrive in the hospital 
environment and infections can be difficult to treat. Widespread multidrug-resistance (MDR) 
and the potential for epidemic spread contribute to the global success of A. baumannii. 
Currently the drugs of choice to treat infections with MDR A. baumannii are carbapenems but 
resistance against these β-lactams is rising, which dramatically reduces available treatment 
options. 
 
The aim of this PhD project was to investigate carbapenem-resistance mechanisms in              
A. baumannii and non-baumannii Acinetobacter spp. This thesis analyses carbapenem-
hydrolyzing β-lactamases in Acinetobacter spp. and gives novel insights into their 
dissemination and genetic context. In addition to the analysis of the metallo-β-lactamase 
NDM-1 in A. baumannii, the work was mainly focused on carbapenem-hydrolysing class D   
β-lactamases (CHDL), including intrinsic and acquired oxacillinases. IS elements were 
frequently associated with carbapenemase genes, involved in their overexpression, disruption 
and potential mobilization. Eighteen novel OXA genes, an OXA subclass (OXA-235-like) 
and an IS element (ISAcra1) were identified. Expansion of the OXA-multiplex PCR with the 
addition of an OXA-235-like primer pair provides an advanced method to monitor CHDL 
distribution in Acinetobacter spp. The results presented here demonstrate that using the   
OXA-multiplex PCR for OXA-51-like detection as the sole method to identify A. baumannii 
is not reliable. 
 
OXA-51-like sequencing and rep-PCR-based DiversiLab revealed correlation of blaOXA-51 
variants with A. baumannii international clonal lineages IC1 to IC8. In the absence of 
acquired OXA, ISAba1 was associated with OXA-51 variants in carbapenem-resistant           
A. baumannii. In addition, outbreak-related A. baumannii isolates revealed a conversion of the 
intrinsic OXA-66 into OXA-82, which was associated with presence of ISAba1 and 
carbapenem resistance. These results suggested that it might be beneficial for A. baumannii to 
harbor one OXA-51 variant over another. 
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This question was investigated on the basis of an isogenic background using A. baumannii 
ATCC 17978 transformants overexpressing four closely related OXA-51-like of the IC2 
lineage; OXA-66, OXA-82, OXA-109 or OXA-201, respectively. OXA-66 converts into 
OXA-201 by two amino acid substitutions (L167V and P130Q), with intermediates 
hypothesized to be either OXA-82 (L167V) or OXA-109 (P130Q). While ISAba1-mediated 
overexpression of OXA-82, OXA-109 and OXA-201 conferred carbapenem resistance in 
ATCC 17978, the OXA-66-expressing transformant remained carbapenem-susceptible. This 
indicates that carbapenem resistance due to ISAba1-mediated blaOXA-51-like in A. baumannii is 
dependent on the OXA-51 variant. 
 
For the first time carbapenem resistance in A. radioresistens and A. bereziniae mediated 
through overexpression of their intrinsic blaOXA associated with an IS element was observed. 
As IS-mediated overexpression of the intrinsic OXA-51-like is the most prevalent 
carbapenem-resistance mechanism in A. baumannii in the absence of acquired OXA, the 
potential of ISAcra1-mediated blaOXA-23 overexpression and IS18-mediated blaOXA-257 
overexpression to spread in the genus Acinetobacter was discussed. 
 
Novel insights into the dissemination and genetic composition of acquired OXA in 
Acinetobacter spp. were observed. For the first time OXA-23 was detected in Acinetobacter 
genomic species 14TU/13BJ and OXA-143, as well as co-expressed OXA-23 and OXA-58 
were identified in A. pittii isolates, which highlighted the spread of acquired OXA in the 
genus Acinetobacter. In addition to Europe and Asia, detection of OXA-23 in non-baumannii 
Acinetobacter spp. from South Africa indicated its global dissemination. For the first time, 
emergence of OXA-143-like in A. baumannii and A. pittii outside of Brazil and South Korea 
was observed. 5´-RACE identified the transcription initiation site of blaOXA-143-like and allowed 
prediction of putative promoter regions. Alignment of sequences upstream of blaOXA-40-like 
revealed the presence of the same putative promoter regions, which is unusual between 
different OXA-subclasses. 
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Alterability of carbapenem susceptibility in A. baumannii was observed under different 
physiological conditions. The effect of NaCl and sodium-salicylate was mainly                 
strain-dependent, while pH 5.8 indicated a potential selective advantage of OXA-23-,      
OXA-40- or OXA-143-expressing A. baumannii compared to OXA-58-like-expressing                     
A. baumannii. In contrast to former publications these results revealed that carbapenem 
susceptibility testing in the presence and absence of 200 mM NaCl is not reliable for OXA 
detection in A. baumannii. 
 
Taken together this thesis illustrates the diversity and variability of carbapenem-hydrolyzing 
β-lactamases in the genus Acinetobacter. The common association of IS elements with 
carbapenemase genes highlighted their influence on genome plasticity. Based on the 
presented data it is tempting to hypothesize that carbapenem resistance will further 
disseminate in the genus Acinetobacter in the foreseeable future. 
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